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ABSTRACT
Analysis and Interpretation of Complex Biological Signal
Transduction Networks
Holly N. Currie
Cellular signaling is a complex system of biological communication that coordinates
cellular activities via biochemical reactions. The passing of an extracellular signal across a cell
membrane to intracellular signaling molecules is referred to as signal transduction. Signals
transduced across a cell’s membrane influence its function, and allow the cell to respond to its
local environment. Within the cell, proteins are key responders to, and carriers of, the
transduced signal. A class of proteins called kinases mediate most of the signal transduction in
eukaryotic cells by catalyzing the phosphorylation of substrate proteins. The post-translational
modification of proteins by phosphorylation regulates protein conformation, thereby influencing
its function and many cellular processes. The multitude of interactions occurring between
proteins within a cell form a complex signaling network that regulates and coordinates
essentially all cellular activities, where reversible phosphorylation serves as a key means by
which proteins can adjust the activity of other proteins. Understanding cellular signaling is a
major challenge facing scientists today. The ability to decipher the complexity of cell signaling
is necessary to thoroughly understand normal biological functions, the pathophysiology of
diseases, and the effects of toxic exposures. A more intimate understanding of cellular signaling
could facilitate the development of improved therapeutic strategies for many diseases and
conditions. Advances in technology have facilitated the collection of large datasets describing
cell signal transduction networks, but it is a challenge to integrate data describing many
individual proteins into concise and meaningful biological knowledge.
A complete
understanding of cell signaling requires the ability to capture and integrate information
pertaining to as much of the entire biological network as possible. This dissertation focuses on
the development and application of an approach suitable for analyzing and interpreting the
networked responses of cells and tissues to stress by monitoring the phosphorylation and
upregulation of proteins. The approach utilized is grounded in the field of graph theory, and
describes networked stress responses based solely on experimental condition-specific data. The
approach’s ability to describe the mode of action for an unknown toxic exposure in vitro is
demonstrated. The approach is also utilized to depict low dose toxicant induced perturbations in
the balance between mitogen activated protein kinase signaling pathways in vitro, providing an
informative and sensitive means of assessing toxicological effects on biological systems.
Finally, the analysis is used to investigate the complex networked response of muscle tissue to
traumatic injury.
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Chapter 1
Introduction to Cellular Signaling and Biological Network Analysis

1

1.1 Introduction
An essential and central aspect of cellular life is that cells must constantly sense and
respond to their local environment. An ultimate goal of experimental and theoretical biology is
to be able to understand and predict how cells will respond to changes in their environment.
Eukaryotic response to environmental factors is coordinated by intricate cellular signaling
networks, which allow cells to accomplish basic cellular tasks such as growth, death, and
differentiation. Understanding cellular signaling is a major challenge facing scientists today.
The ability to decipher the complexity of cell signaling is necessary to thoroughly understand
normal biological functions as well as the pathophysiology of diseases, and could facilitate the
development of improved therapeutic strategies for many diseases and conditions.
Previous approaches used to study the biochemical signaling mechanisms responsible for
the orchestration of biological processes have primarily focused on the isolated study of
particular genes or proteins believed to be associated with distinct functions or conditions of
interest.1 Recent technological advances and increased computational power have exposed the
complex and dynamic networked nature of cellular signaling, making it evident that studying
isolated portions of biological systems can lead to an under informed and even faulty
understanding of the system.2,
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This is because all components of biological systems are

connected as a network, making it possible for even distant components to have an effect on each
other. Individual elements of biological systems do not function alone, and are not solely
responsible for the control of a biological process or response. Biological functions are carried
out by a coordinated effort between multitudes of network components. The architectures and
regulatory mechanisms that govern network responses are extremely complex.

Events or

perturbations occurring at particular locations within these networks often have unpredictable
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effects at other localities within the network. The ability to forecast and understand networked
biological responses to environmental stimuli is a challenging goal, important to the progression
of many fields including molecular biology, pharmacology, and toxicology.4-6 There is a current
need for network analysis approaches that are capable of describing the collective functioning of
the expansive number of network components that comprise biological systems.
A complete understanding of cell signaling requires the ability to capture and integrate
information pertaining to as much of the entire biological network as possible. This body of
work focuses on the development and application of an approach suitable for analyzing and
interpreting the networked responses of cells and tissues to stress. The approach utilized is
grounded in the field of graph theory. Chapter 1 discusses the basics of cell signaling, the
cellular stress response, techniques used to study cell signaling, and the utility of graph theory
for the analysis of biological networks. Chapter 2 presents the application of the network
analysis to determine xenobiotic toxic modes of action in HepG2 cells. Chapter 3 concerns the
analysis and interpretation of the networked cellular response to mitochondrial stress. Chapter 4
covers the expansion the analysis to the more complex network response of tissue to traumatic
injury stress. This work covers research that has been published in:

Currie, H.N., Vrana, J.A., Han, A.A., Scardoni, G., Boggs, N., Boyd, J.W. An Approach to
Investigate Intracellular Protein Network Responses. Chemical Research in Toxicology. 2014
27(1), pp 17-26.
Currie, H.N., Loos, M.S., Vrana, J.A., Dragan, K., Boyd, J.W. Spatial Cytokine Distribution
Following Traumatic Injury. Cytokine. 2014. 66(2), pp 112-118.
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1.1.1 Cell Signaling
Cell signaling is the complex system of communication and information flow present
within living organisms that governs virtually all cellular activities including proliferation,
differentiation, and cell death.7 Simply stated, cell signaling is the way in which cells perceive
and respond to their environment. In cellular systems, extracellular signals (released from other
cells or present in the organism’s environment) in the form of hormones, steroids, xenobiotics,
protein ligands (cytokines/growth factors), or mechanical forces are converted into intracellular
signals at target cells through interactions with cell surface receptor proteins in a process referred
to as signal transduction.
Transmembrane receptor proteins typically span the cell membrane having an
extracellular and intracellular domain.8 The interaction between the ligand and receptor induces
a conformational change in the receptor protein that leads to transmission of a signal across the
plasma membrane via alteration of the activity of the intracellular portion of the receptor towards
an intracellular signaling molecule. This triggers an intracellular signal transduction cascade
where the activated intracellular signaling molecule goes on to interact with other molecules,
typically signaling proteins, which further interact with other signaling molecules, and so on.
Through this series of signaling interactions the cascade may eventually reach a protein, that
once activated, will translocate from the cytoplasm to the nucleus where, through interactions
with transcription factor proteins, the gene expression of the cell is altered. Signaling molecule
interactions can lead to activation or deactivation of protein activities.9 Individual proteins can
have multiple interaction sites that result in different protein functionalities.10, 11 Cells constantly
and simultaneously receive numerous signals which affect multiple intersecting and overlapping
signal transduction pathways. These pathways form a complex network that allows cells to
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integrate multiple environmental signals, and respond with outputs specifically tailored to the
environmental conditions.

1.1.2 Kinases
One of the largest, most prevalent, and well studied groups of signaling proteins are the
protein kinases.12

There are more than 518 known human protein kinases accounting for

approximately 1.7% of the human genome.13, 14 Protein kinases are intracellular enzymes that
catalyze the transfer of the γ-phosphate group from abundant ATP molecules within the cell, to
the hydroxyl groups on serine, threonine, or tyrosine residues of specific protein substrates (often
other kinases).15 This phosphorylation reaction is shown in Figure 1-1. The addition of a
phosphate group covalently modifies the substrate protein, changing hydrophobic regions to
hydrophilic, thereby altering the protein’s conformation.16 The conformational change can alter
the substrate protein’s function in several ways, including activation or deactivation of its
enzymatic activity, blocking binding sites for other proteins, or affecting its stability.12
Phosphorylation is a highly effective, reversible way of regulating the protein activities, that
mediates the majority of signal transduction in eukaryotic cells, and controls almost all cellular
processes

including

metabolism,

transcription,

cell

cycle

progression,

cytoskeletal

rearrangement, cell movement, apoptosis, and differentiation.13
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Figure 1-1. Phosphorylation reaction

Protein kinases are activated when induced conformational changes cause their catalytic
domains to become accessible to both ATP and substrate proteins. The amino acid residues in
the catalytic domain work to precisely position the ATP molecule so that the γ-phosphate group
is aligned to facilitate its transfer to a hydroxyl group on the substrate protein.14 Activated
kinases will only recognize and phosphorylate an amino acid if it is surrounded by a specific
consensus amino acid sequence.14

The degree of specificity kinases have towards their

substrates varies from kinase to kinase.17 Some kinases will only phosphorylate a single protein
or a few closely related proteins, while other multifunctional kinases can target many different
proteins. The specificity is primarily determined by the amino acid residue interaction between
the catalytic domain of the acting kinase and the amino acid residues near the phosphorylation
site of the substrate protein. However, based upon quaternary structure, distant residues can
sometimes also contribute to the specificity.17
Protein phosphatases can regulate kinase activities by catalyzing the hydrolytic removal
of phosphate groups from proteins.

Protein phosphorylation and dephosphorylation are

essentially irreversible under physiological conditions, and take place at negligible rates in the
absence of enzymes.18 Thus, protein phosphorylation and dephosphorylation typically only take
6

place by way of the action of specific protein kinases (at the expense of ATP cleavage) or
phosphatases, respectively.

This cycle of phosphorylation and dephosphorylation forms a

complicated and sophisticated signaling network of kinases and other effector molecules that is
essential to the orchestration of many important biological processes.13

1.1.3 Mitogen-activated Protein Kinases
The mitogen-activated protein kinases (MAPKs) are a group of kinases that have been
extensively studied due to their fundamental involvement in a wide range of cellular processes
including cell growth, differentiation, death, survival, and the immune response.19

The

deregulation of MAPK signaling is associated with many diseases such as cancer, inflammatory
disease, and diabetes.20 MAPKs are conserved in eukaryotes, and are among the oldest signal
transduction pathways essential to many physiological processes throughout evolution.21
MAPKs allow cells to respond to a variety of extracellular stimuli including growth
factors, hormones, cytokines, neurotransmitters, and xenobiotics. They form signal transduction
cascades that respond to receptor level stimulation, and transfer signals to targets in both the
cytosol and nucleus. The binding of ligands to transmembrane receptors leads to the activation
of small Ras/Rho family GTP proteins that activate the first kinase in the MAPK cascade
referred to as a MAPK kinase kinase (MKKK).21, 22 This MKKK phosphorylates and activates a
MAPK kinase (MKK) on either Ser or Thr residues.21, 22 The activated MKK then goes on to
dually phosphorylate a MAPK on Thr and Tyr residues leading to its activation.21, 22 Activated
MAPKs bind to specific docking sites on their target proteins and phosphorylate them at Ser or
Thr residues that are usually followed by a Pro residue.19 MAPK signaling modules can have
interactions with many other regulatory proteins such as phosphatases and scaffold proteins.23
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Scaffold proteins can act to co-localize two MAPKs to facilitate their interaction, and represent a
mechanism for regulating MAPK signaling. Activated MAPKs can translocate into the nucleus
where they can phosphorylate proteins involved in transcriptional regulation.19

A simple

schematic of a MAPK signaling cascade can be seen in Figure 1-2.

Stimuli
(Stress, Cytokines, Growth

Factors, Mitogens, Physical
Agents)

MAPKKK

MAPKK

MAPK

Transcription Factors,
Cytoskeletal Proteins,
Other Protein Targets

Specific Biological Response
Growth, Proliferation,
Differentation, Migration, Stress
Defense, Apoptosis, etc

Figure 1-2. MAPK signaling cascade.

1.1.4 Kinases as Xenobiotic Targets
Alterations in normal kinase functioning and subsequent perturbation of protein kinase
signaling has been related to pathological changes and diseased states such as cancer, diabetes,
atherosclerosis, inflammatory diseases, Parkinson’s disease, and Alzheimer’s, making kinases
8

popular therapeutic targets.8, 24 Many drugs are designed to target specific kinases by exploiting
their differences and binding to unique structural features. This binding interferes with the
kinase’s normal signaling activities, and offers a means of modulating the kinase’s functioning.
ATP competitive inhibitors are small molecules designed to competitively bind to and occupy
the ATP-binding pocket within a kinase’s catalytic domain, thereby preventing the kinase from
phosphorylating other proteins.

Substrate competitive inhibitors mimic substrate proteins,

thereby preventing the kinase from phosphorylating its endogenous substrate.25 Other inhibitors
interact with regulatory protein domains preventing the kinase from becoming active.

In

addition to their use as therapeutics, kinase inhibitors are also widely used as probes to study the
physiological functions of proteins.

A caveat underlying the use of kinase inhibitors as

therapeutic and investigative tools is in the inhibitor’s specificity. Compounds can inhibit a
number of different targets making it difficult to be certain that the intended target is the only
one being directly affected.25-27
Traditionally, kinases were described as members of distinct linear signaling pathways.
This made therapeutic strategies involving the modulation of a single target appear viable.28
However, single target therapeutic strategies have extremely high failure rates, and many kinase
targeted drugs induce undesirable side effects that are difficult to foresee.29 These difficulties are
reflected in the 30-year decline in pharmaceutical development productivity in spite of increased
spending by the pharmaceutical industry, and the multitude of improvements in ‘omics’
technologies that have provided expansive datasets describing cellular functioning.30

This

trouble in developing successful monotherapies can be partially attributed to the fact that kinases
function as large, complex, and dynamic networks, rather than distinct linear pathways.28 The
dynamic nature of these networks makes it challenging to predict how they will respond to any

9

perturbation. The high degree of interconnectedness between network components makes it
likely that altering one specific protein will affect others. Actions directed at specific targets can
radiate throughout the network, and manifest as undesired drug side effects.6
Cell signal transduction networks have evolved over billions of years to be able to
withstand a variety of insults and disruptions.

This entails backup mechanisms that can

compensate for compromised network components. It is the high degree of connectivity in
kinase networks that imparts tolerance and robustness towards deleterious events directed at
single or a few node components in biological systems.31 If one avenue of communication is
compromised, there are many other possible routes available for the transmission of important
signals necessary for normal functioning and survival. This is especially true in the case of
cancer cells, and explains why it can be difficult to treat cancer with single target regimens. The
underlying architecture of signaling networks affects their function, and knowledge of this
architecture is necessary to develop better treatment strategies. Indeed, recent years have seen a
shift in drug discovery from targeted discovery to network pharmacology.6,

27, 32-35

It is now

realized that therapeutic strategies are in need of a more intelligent design, where diseases are
treated as rewired or unbalanced networks instead of single mutated genes or proteins.27,

36

Current therapeutic approaches could be enhanced by assessing diseases at the network level,
and by evaluating the entire network response to therapeutic treatments. This requires the
development of methods capable of characterizing and understanding the context specific,
dynamic, and complex functioning of biological networks.
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1.1.5 Monitoring Kinase Signaling
Signaling can be studied at the level of the whole organism, at the level of individual
cells, or at the level of isolated proteins or peptides. There is currently no approach or method
that can capture the entire range of kinase interactions occurring in real time in a given biological
system. There are many different approaches to studying kinase signaling, each with their own
advantages and disadvantages.37-44 The simplest level seeks to identify possible substrates of a
kinase. The identification of biologically relevant kinase substrates has historically been a slow
and laborious process that often yields unreliable results,37 and still remains a difficult task.
Possible kinase substrates are often determined by incubating the isolated kinase of interest with
putative substrate proteins or peptides in the presence of ATP and Mg2+, and then detecting
which proteins/peptides became phosphorylated. These low throughput approaches can lead to
the identification of kinase interactions that may not actually occur, because the behavior of
interacting proteins can be significantly different in an intact biological system in comparison to
when isolated.38 Just because a kinase can phosphorylate a target does not mean that it will in a
living system. The use of highly concentrated purified kinases in these assays can cause a kinase
to phosphorylate a substrate that it would not normally phosphorylate in vivo38. Removing a
kinase from its cellular environment leads to a loss of physiological regulatory mechanisms. For
example, if a third protein is necessary for the interaction between a kinase and its substrate to
take place, the isolated analysis will not identify the interaction. X-ray crystallography can be
used to visualize kinases bound to their substrates, and has contributed significantly to the
current knowledge of kinase interactions.39 However, this only provides a static picture, and
does not effectively capture the dynamics of phosphorylation processes in real systems.
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Other approaches seek to directly detect interacting kinases in living cells. Techniques
used in these approaches include yeast-two-hybrid assays and Förster Resonance Energy
Transfer (FRET).40,

41

These approaches involve altering cells by genetically fusing proteins

with large adducts which can lead to alterations in the studied protein’s normal activity, and may
not accurately reflect its activity.41, 42 These techniques are also limited to studying a few kinases
at a time making it difficult to capture network dynamics.

Additionally, protein-protein

interactions occurring during phosphorylation are considered transient with interacting proteins
quickly dissociating following the phosphorylation event, making the event difficult to capture.12
Other less direct approaches primarily rely on determining the amount of each protein
that is phosphorylated following varying degrees of stimulation or perturbation.

This is

commonly in the form of growth factors, kinase inhibitors, or genetic silencing/deletions.41-43
Kinase relationships are inferred based upon changes in the amount of each phosphorylated
protein in response to the stimulation or perturbation. These approaches can monitor many more
proteins than the more direct approaches, but cannot definitively identify which proteins are
interacting. This is the type of approach utilized in this body of work.
Detecting phosphorylated proteins is also technically challenging due to the dynamic and
reversible nature of phosphorylation, and the fact that the ratio of phosphorylated to
unphosphorylated proteins in living systems is relatively low.16,

43

The identification of the

amount of phosphorylated protein does not reflect the connections between kinases or the role
that they play in the signaling network.

Elucidating the structure and function of kinase

signaling networks is an especially challenging task. New technologies have facilitated the
collection of large phosphoproteomic datasets revealing intricacies of cell signaling that were
previously unknown,43 but this wealth of information presents issues in interpreting the data into
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meaningful and relevant knowledge. There is a current need for approaches that are capable of
integrating this data to describe the networked response of kinases to stimulation or stress, and
this body of work presents an approach used to concisely describe networked cell signaling
responses based on condition-specific phosphorylation data.

1.1.6 Multi-plexed Bead-based Immunoassays
In the work presented here, a multiplexed bead-based immunoassay suspension array
platform was used for targeted phosphoprotein analysis. This platform is attractive due to its
ability to perform multiplexed analyses including as many as 100 protein targets, in 12.5 µl of
sample, in as little as 3 hrs, and with a relatively simple work flow.44 The platform utilizes
polystyrene microbeads that are uniquely coded with varying concentration ratios of two internal
fluorescent dyes.45-47 Phospho-specific antibodies are immobilized on the surface of microbeads
that have dye ratios designated to code for the particular target for which the antibody
recognizes. Microbeads with different antibody coatings (and dye codes) are incubated with the
sample in a single reaction well to achieve multi-analyte analysis.

Following incubation,

biotinylated secondary antibodies are added to the reaction well. Unbound secondary antibodies
are washed away, and the microbeads are incubated with the fluorescent reporter, streptavidinphycoerythrin conjugate. Analysis is performed using a flow cytometer with lasers to identify
the coded beads and to also detect the fluorescent phycoerythrin reporter. Figure 1-3 shows a
representation of an analyte captured by the bead sandwich immunoassay.
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Figure 1- 2. Bead sandwich immunoassay

The microbead platform was selected for the analyses performed in this body of work due
to its fast, cost effective, simple work flow, availability of standardized protocols, and
multiplexing capabilities necessary for analyzing network responses. This technology has been
extensively optimized and validated and has a broad dynamic range.48 The suspension array
platform was also chosen because cytokines were also targets of interest to this work. Cytokine
concentrations can span a wide concentration range in biological samples,48,49 exceeding the
dynamic range achievable by many instruments used in proteomic studies. Antibody based
approaches including the microbead platform utilized here have suitable dynamic ranges for
cytokine analysis.49 In the work presented here, the microbead multiplexed platform was used to
identify changes in both total protein levels and phosphorylated protein levels in cells and tissues
subjected to stress.

1.1.7 Stress Responses
Cells constantly sense their environments, which allows them to detect any type of stress
and quickly adapt to survive.50-53

When whole organisms, organ systems, and tissues are

subjected to environmental stressors, their responses are a direct result of the coordinated
14

responses of individual cells mediated by signal transduction networks, and thus, cell signal
transduction cascades are fundamental to stress responses. As a necessity for survival, all cells
have developed defense mechanisms capable of responding to a wide variety of cellular threats.
These mechanisms can be quite sophisticated and are referred to as cellular stress responses.
Cellular stress responses have extraordinary physiological and pathological significance. A
cell’s fate after experiencing stress is dependent upon the type of cell, the proteome expressed at
the time the stress is experienced, the nature of the stress, and the stress’s magnitude and
duration.52, 54
Eukaryotic cells have evolved to contain signal transduction networks capable of
producing dynamic and coordinated responses that can alter virtually any cellular process to
adapt to a perceived stress.50,

52

Immediate responses are carried out by post-translational

modifications such as phosphorylation, while long term adaptations are in the form of alterations
to gene expression.50,

52

Cellular stress responses frequently involve common evolutionarily

conserved core stress response proteins, but can also utilize diverse molecular mechanisms.50, 52,
55, 56

Stress responses involving evolutionarily conserved stress proteins, such as heat shock

proteins, are typically induced by deformation or damage to macromolecules, and aim to sense
and mitigate protein damage, DNA damage, or altered cellular redox states.53,

55, 57

Many of

these types of stress responses have been well characterized,54 and are sometimes rather simple
in nature. For example heat shock or unfolded protein stress responses can be as simple as
increasing the expression of chaperone proteins that assist damaged proteins in reestablishing
their proper conformations.
Cells use multiple signaling pathways to respond to environmental changes and stresses,
including survival signaling and destructive death signaling pathways. Survival signaling aims
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to push cells towards recovery while death signaling aims to remove cells that have been
damaged beyond the point of recovery. Whether or not a cell will survive under conditions of
stress is dependent on the network balance between survival promoting signaling and death
promoting signaling, between which complicated interplay exists.58 The molecular mechanisms
that control the balance between survival and death signaling and determine whether or not cells
will survive under periods of stress are not fully elucidated. MAPK signaling is essential to the
coordination of cellular responses to a wide variety of stresses including chemical exposure
stress and physical stress.50, 51, 55-57, 59-66 MAPK stress signaling is susceptible to regulatory input
at all levels of their cascades via multiple mechanisms, including modification of MAPK
subcellular localization, stimulus intensity, scaffold protein interactions, phosphatase activity,
positive and negative feedback loops, and cascade crosstalk.56 Cell survival/death decisions are
heavily influenced by MAPK signaling, and understanding this influence can provide valuable
insight into the effects of stresses.57,

67-69

However, the complex networked relationships

between MAPKs, as well as the variety of ways MAPK signaling can be regulated makes it
particularly difficult to decipher how MAPK signaling coordinates responses tailored to each of
the many stresses a cell experiences.
The ability to predict how cells will respond to any type of stress is extremely desirable to
many disciplines.

Many aspects of the cellular stress response remain poorly understood,

especially with regard to post-translationally regulated responses in human cells.52, 53 This can
be attributed to the current lack in understanding of the integrated functioning of the numerous
signaling proteins present in human cells, as well as the variability that exists amongst different
cell types.53 The numerous and diverse proteins that coordinate cellular responses, together
comprise a complex cellular network through which information flows.

A comprehensive
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understanding of how the flow of information through cellular networks coordinates their
functioning and changes in order to sustain life remains elusive. The complexity of cellular
signal transduction networks necessitates a global network analysis integrating comprehensive
datasets to fully capture and understand how cells respond to stress.52, 70 An understanding of
cellular responses to stress is of profound importance when assessing toxicological risks and
understanding disease pathophysiology.
The true complexity of cell signal transduction networks is now becoming apparent. It
has become evident that more creative alternative network comprehensive approaches are needed
to better investigate complex cell signaling. Networks are universal and important focal points
of many disciplines. The field of mathematics referred to as graph theory has found widespread
applicability in the study of complex networks across many disciplines. In the work presented
here, graph theory was utilized to analyze and interpret signal transduction network responses to
stress.

1.2 Graph Theory
Networks pervade all avenues of life from social circles, the internet, power grids, and
food webs to the citation networks of scientists.71

Networks are inherently difficult to

comprehend. A major challenge facing scientists today is how to accurately describe and
understand how individual components of complex systems function together as a network.
Analysis of the topology of complex networks can provide valuable insight into how complex
networks operate.

The topological organization of complex networks determines how

information will flow throughout the system, and how the system functions. Networks are
further complicated when the many connections between their elements are capable of changing,
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and the various connections have different strengths or weights. Due to their large size and
complex interactions, describing the topological organization of many commonly encountered
networks can be a lengthy and laborious task.72 Graph theory is a valuable mathematical
modeling tool that can be used to characterize the global topological organization of networks.
Graph theory was initiated in 1736 by Leonhard Euler to solve the Seven Bridges of
Königsberg problem.73 There were 7 bridges in the city of Königsberg that spanned various
sections of the River Pregel. It was often questioned whether or not a path existed by which a
person could cross each bridge only once and return home. Euler mathematically proved that it
was in fact impossible to only cross each bridge once, and in doing so laid the foundation for
graph theory.74 Since then, graph theory has been used to solve basic practical problems such as
determining the maximal flow rate of water flowing from a source sink to a network of pipes,
and more recently, to more involved and complex problems such as characterizing how group
memberships (political, religious, or corporate board membership for example) within human
networks affect the spread of attitudes and opinions.75

1.2.1 Graph Theory Basics
In graph theoretical analyses, a network of interacting elements is depicted as a graph
consisting of nodes and edges. Nodes can represent any element contained within the network.
Edges connect pairs of nodes, and represent the interaction or relationship (if one exists) between
node pairs. Based on the connectivity of the graphs and any edge weightings, quantitative
attributes that characterize the structure and behavior of networked systems can be calculated.7579

Network edges can be directed or undirected. Directed edges depict relationships for which

there is a known source node and target node. The Internet is an example of a network with
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directed edges. Networks in which the relationships between each node are mutual, such as
human social networks, are undirected. Quantitative descriptors of connection strength or the
amount of information flow between nodes can be utilized as edge weights.80 Quantitative
parameters calculated using graph theory that concisely describe the topology of an entire
network as a whole are referred to as network parameters. Other quantitative parameters,
referred to as node centralities, describe the relevance of an individual node with regard to the
rest of the network.
Pioneering work establishing the basic measures and techniques used in graph theory
today was performed in the mid-twentieth-century by Erdos and Renyi.81 Erdos and Renyi found
that probabilistic methods were quite useful in solving graph theory problems, and from their
work, predicted that real complex networks could be modeled as random graphs.72, 81 Random
graphs are homogeneous graphs, where all nodes in the graph are wired together at random. This
results in a binomial node degree distribution indicating that all nodes have approximately the
same node degree (number of direct connections to other nodes).78 In the random graphs
described by the Erdos Renyi (ER) theory, nodes with a relatively high connectivity or degree
are practically absent. Random networks display small world characteristics, meaning that all
nodes in a network can easily communicate with each other, either directly or through a
relatively short path length or series of “go between” nodes.78 The small-world effect is the
basis for a popular game called six degrees of Kevin Bacon in which players must connect Kevin
Bacon to any given actor or actress through the shortest possible path of film collaborations.82, 83
Small world characteristics allow for fast communication within networks.

Following the

development of ER theory, it was generally accepted that the majority of real complex networks
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encountered followed the principles of ER theory, but large datasets and the computational
power needed to thoroughly test this theory were not available.
Recently, the availability of large datasets describing complex networks, the emergence
of databases to upload and share this data, and increased computational power have allowed the
random ER theory to be tested on networks spanning various disciplines.72 Two seminal papers
were published that led to an explosive interest in the field of network science by changing the
accepted views on real network structures. The first, published by Watts and Strogatz in 1998,
proved that networks that are disordered, highly clustered, and non-random can have small world
characteristics just as random graphs. Watts and Strogatz demonstrated that 3 real networks, the
United States power grid, the collaboration graph of film actors, and the neural network of the
worm, abided by the small world phenomenon.84 They suggested that most other real networks,
including biological networks, likely display small world properties as well.
The second paper, published by Barabasi and Albert in 1999, demonstrated that networks
across diverse fields of science share properties that do not fit the random ER graph model.72
They found that real networks display a high degree of self-organization, and that their node
degree probability distributions decay as a power-law. Meaning that large networks organize
into scale-free states, where a few nodes are likely to have a high connectivity or degree, while
the majority of nodes in the network have a low connectivity. Barabasi and Albert demonstrated
that the random graph models failed to represent real networks, because they did not account for
growth and preferential attachment that occur in most real networks.

Most real networks

continuously grow by incorporating new nodes into their structures. When new nodes are added
they preferentially attach to nodes in the network that already have a high degree of connectivity.
Therefore, nodes with a high degree will continue to increase in connectivity while nodes with a

20

low degree will remain low in connectivity. This realization, that many real networks display
small world and scale-free properties, had considerable implications in the field of network
science, because these types of network architectures could be used to explain why many real
networks are functionally robust.75

1.2.2 Graph Theory and Biological Networks
Traditionally, biochemical interactions were thought of as individual linear pathways
where enzymes acted upon substrates to form products. In the post-genomic era it became
evident that many proteins interact with multiple other proteins in complex network structures
rather than in a series of linear reactions, and are better modeled using graphs representing the
networked nature of biochemical processes.85, 86 In the past decade, many datasets describing
molecular interactions (as well as maps of specific cellular networks) have been compiled, and
graph theory has been applied to these datasets to characterize the properties of biological
networks.87-91
In the decade following the publication of the seminal papers by Watts and Barabasi,
there was a flood of new research characterizing the topological structures of many real
networks.92 This research has shown that many real networks, regardless of their function, have
similar architectures.

Biological networks are among these real networks found to have

universal architectures.87,

92-95

Biological networks were shown to display small-world

characteristics. This characteristic is important for efficient responses to network perturbations,
and ensures that information can propagate throughout the network quickly even when some
nodes have been compromised.94 The first demonstrated scale-free biological network was the
worm neural network from the seminal paper published by Barabasi in 1999.72 In 2000, Jeong et
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al determined that the core metabolic networks of 43 organisms from all 3 domains of life
(eukaryotes, bacteria, and archaea) displayed both scale-free and small-world architectures,96 and
in 2001 they demonstrated that the protein-protein interaction network of yeast was also scalefree.95 Since then, many other biological networks have been shown to be scale-free and display
small-world properties.94, 97-99
It has been postulated that the scale-free architecture of biological networks is important
to the survival of cellular life, and explains the robustness of cellular systems towards random
attacks.31 If a node is attacked or fails at random in a scale-free network, probabilistically it is
most likely that the node has a low connectivity, and the attack or failure will only affect the few
nodes directly connected to or near that particular node. Communication amongst the majority
of the network will not be interrupted by the attack/failure. This provides biological networks
with a high degree of tolerance towards random attacks or node failures.95

While this

architecture imparts robustness to cellular networks, it can also be exploited as a weakness by
targeted or intelligent attacks. The targeted attack of highly connected “hub” nodes can be
massively destructive to scale-free networks.92, 95, 100
This relationship between network structure and robustness demonstrates the importance
in understanding the networked relationships of complex systems, which can also apply to
cellular signal transduction networks. Understanding the topological characteristics of signal
transduction networks is key to understanding how cells respond to their environment, and can
provide a better understanding of diseased states. This can provide valuable insight for the
development of effective therapeutics as well as a better understanding of the toxic effects of
both pharmaceutical and environmental xenobiotics.
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A few studies have sought to determine the architecture of cancer signaling networks.101,
102

Schramm et al analyzed the network characteristics of eleven different tumor types and

corresponding non-malignant tissue samples, and found that both tumor, and normal signaling
networks display scale-free characteristics.101 They found that the cancer cells had shorter
average path lengths, were less centralized, were less reliant on hub proteins, and were more
robust against targeted hub attacks in comparison to the non-malignant samples.

These

differences likely explain why cancer is difficult to treat using single target therapies. They and
others also found that cancer specific mutations occur most often at hub proteins.101,

102

It is

important to note that the networks constructed in these studies were all based on correlations in
gene expression. To fully capture the characteristics of signal transduction networks, post
translational modification events, specifically phosphorylation, should be incorporated into the
analysis. Ideally network analyses would be based on the directional transfer of phosphate
signals through the network, but it is not currently possible to actually detect or observe the
numerous interactions of proteins and transfers of phosphate groups occurring in living
biological systems. This body of work presents an approach that extracts information pertaining
to the networked relationships of kinases based on condition-specific protein phosphorylation
data.
There are other major limitations and obstacles hindering a complete and predictive
understanding of cellular networks. Most graph theory applications to biological networks fail to
provide direct representations of actual cellular networks. This is because the vast majority of
studies investigating biological networks rely on databases for determining the network
structures. This is problematic because the databases cull data from experiments performed
using a variety of different species, cell types, and experimental conditions, and therefore,
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represent more of an averaged network structure across various studies. In reality, biological
networks are extremely diverse and require data-driven models for accurate depictions.
An ultimate goal of experimental and theoretical biology is to be able to understand and
predict how cells will respond changes in their environment. This goal requires an intimate
understanding of the structure and dynamics of the network of biological molecules that together
make up the cell. Real biological networks are extremely dynamic with nodes and edges that can
be added, deleted, or altered depending on the specific circumstances. However, most studies
only determine the static topological structure of biological networks. Studies that only depict
the static structure of biological networks fail to capture the dynamics of the processes that occur
on these network structures. Characterizing dynamic processes occurring on network structures
remains a challenge to network analyses across all fields. Most graph theory network analyses
are based on qualitative descriptions of network connectivity. The next frontier and challenge is
to make these analyses quantitative by integrating experimental data into the graph theory
analysis and placing it onto the networks to capture the network dynamics.86,

88

The use of

weighted edges is relatively uncommon in most graph theoretical analyses, including biological
network analyses, even though it is useful in describing network dynamics based on
experimental data.75 This body of work concerns the development and application of a novel
graph theoretical network analysis approach that aims to address some of the obstacles currently
facing biological network analyses.

Importantly, this approach integrates experimentally

obtained data with graph theory analysis using weighted edges, providing a means to capture the
specific dynamic changes that signaling networks undergo in response to specific environmental
stresses.
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Chapter 2
Network Analysis Approach to Determine Xenobiotic Toxic Modes
of Action
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2.1 Introduction
Our understanding of cellular functioning has increased significantly over the past few
decades. As our view of the cell and intracellular signaling expands, it becomes more and more
difficult to delineate how all of the individual cellular components engage to form the
sophisticated communication systems that coordinate biological processes. The architecture of
signaling networks inherently influences their function.1 Current toxicological mode of action
(MOA) evaluations seldom consider network relevant information, even though xenobiotic
effects are ultimately guided by the response of the signaling network. In this chapter, a novel
graph theoretical approach to analyze networked biological responses to toxicological insult is
presented. The approach is utilized to provide a network relevant description of a xenobiotic
MOA. Importantly, this approach integrates experimentally obtained data with graph theory
analysis, providing a means to capture the specific dynamic changes that signaling networks
undergo in response to specific xenobiotic exposures.

2.1.1 Mode of Action Analyses
An important component of human toxicological risk assessments is identification of a
compounds MOA. Determining the MOA by which uncharacterized xenobiotics lead to adverse
effects is currently a challenging task. Determination of just one compound’s MOA requires
years of effort, and there are currently tens of thousands of environmental and pharmaceutical
compounds with unknown toxic MOAs.2-5 In spite of extensive efforts, the cellular targets of
many toxic xenobiotics remain unknown.5,

6

This can be partially attributed to difficulties in

identifying a few principal protein targets when there are thousands of other proteins functioning
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together as complex and dynamic biological signaling networks to coordinate the cell’s response
to toxic exposure.
The initial pharmacodynamic response to xenobiotic exposure is predominantly
coordinated by signal transduction networks that follow the simple framework of protein
phosphorylation and dephosphorylation carried out by kinases and phosphatases.

This

framework yields a complex cellular signaling network consisting of thousands of proteins, of
which any can be targets in the xenobiotic toxic MOA.7, 8 The vast size and dynamic nature of
signaling networks makes it a challenge to identify the primary target(s) of uncharacterized
xenobiotics. Though difficult in itself, identification of the primary xenobiotic target falls short
of providing a complete understanding of the toxic effects of a chemical exposure. Toxic actions
can and will propagate throughout cellular networks, sometimes affecting seemingly distant
components. The propagation of pharmaceutical actions throughout a signaling network is
sometimes responsible for undesired side effects.9,
compounds interact with at least 6 targets.11,

12

10

It is believed that most pharmaceutical

Xenobiotic promiscuity can induce multiple

propagations throughout the network, further complicating the determination of the toxic MOA.
It is difficult to fully capture the toxic mechanism of action for an uncharacterized compound
without considering the networked nature of the cell. Approaches that can accurately and
efficiently describe xenobiotic MOAs from a network perspective have the potential to save the
pharmaceutical industry a substantial amount of time and money while leading to the
development of safer therapeutics.10
Current methods of determining toxic MOAs involve years of testing single compounds,
primarily utilizing long term whole animal studies and a battery of in vitro assays.13-16 The data
obtained from these extensively studied compounds is then incorporated into large reference
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libraries. The MOA for other compounds can then be predicted in a shorter time frame with
fewer resources by generating an activity profile for the compound using just a few assays and
comparing the results to those in the reference library.17-22 These activity profiling approaches
still require a considerable amount of time and resources, and are limited to identifying MOAs
that are contained within the reference library.

Such approaches are not well suited for

evaluating unique compounds that do not exhibit activities similar to those of well studied
compounds.
Quantitative structure activity relationship (QSAR) information is also used in MOA
analyses to identify potential xenobiotic targets. QSAR approaches predict targets by comparing
the structural properties of the studied xenobiotic to reference compounds with known protein
targets and activities.21,

23-27

Compounds can also be reacted with large reference panels of

isolated proteins to identify potential target interactions as part of MOA analysis.12 However,
simply identifying the proteins possibly bound by a molecule does not effectively capture the
network wide effects of the compound, nor describe how these effects contribute to the
progression towards toxicity. Additionally, isolated proteins do not accurately reflect the native
environment of proteins within signaling networks, as toxicity can be an emergent property of
the network and its structure. Also, there is always a chance that the target for which the
compound has the highest affinity is not in the reference set.28, 29
While these currently used methods of evaluating xenobiotic MOAs are informative,
there is a need for more efficient and more network comprehensive complimentary approaches
that are capable of rapidly characterizing a specific biological systems’ response to xenobiotic
exposure (based only on data from that system), while identifying key proteins involved in the
MOA. This chapter demonstrates the ability of a newly developed network analysis approach to
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efficiently identify primary xenobiotic targets and other proteins important to a xenobiotic toxic
MOA. As a proof of principle, the approach’s ability to assess a MOA is tested using a
xenobiotic known to selectively inhibit glycogen synthase kinase 3 (GSK-3).
2.1.2 GSK-3 and TDZD-8
GSK-3 is a multifunctional protein involved in the regulation of a diverse array of
cellular activities.30, 31 GSK-3 is highly conserved across species, and exists as two isoforms,
GSK-3α and GSK-3ß.

Both isoforms are expressed ubiquitously in tissue.32

GSK-3 has

received significant attention as a therapeutic target due to its involvement in a variety of
pathological conditions including type II diabetes, muscle wasting, cancer, neurological
disorders, inflammation, and Alzheimer’s.33 It was originally discovered as a protein involved in
glycogen metabolism, but is now seen as a complex nexus protein capable of interacting with
many different substrates and multiple signaling pathways.32 Few enzymes exert more influence
over cellular function than GSK-3, and GSK-3 is one of the kinases with the greatest number of
identified cellular substrates.34 There are multiple mechanisms by which GSK-3 activity is
regulated including phosphorylation and autophosphorylation, protein complex association,
substrate priming, subcellular localization, and proteolytic cleavage.30,

32

While all of the

regulatory mechanisms for GSK-3 are not fully understood, GSK-3 is known as a dual
specificity kinase that is differentially regulated by Tyr and Ser/Thr phosphorylation32. GSK-3 is
positively regulated by phosphorylation on a Tyr residue (Tyr-279 on GSK-3α and Tyr-216 on
GSK-3ß), and negatively regulated by N-terminal phosphorylation of Ser residues (Ser-21 on
GSK-3α and Ser-9 on GSK-3ß).32,

35, 36

The Ser residues can be phosphorylated by several

protein kinases including AKT, p90RSK, and p70S6 kinase.32 An uncommon feature of GSK-3
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is that it is catalytically active in the absence of extracellular stimulation, but in response to
extracellular signals its enzymatic activity rapidly decreases.37
Over 100 cytoplasmic and nuclear proteins have been identified as GSK-3 substrates.32
A rare feature of GSK-3 is that many (but not all) of GSK-3’s substrates must first be primed by
phosphorylation before GSK-3 will act on them.37, 38 These substrates span various functional
types of proteins including those involved in metabolism, cellular architecture, gene expression,
neurobiological processes, immune responses, circadian rhythms, differentiation, proliferation,
growth, insulin response, death and survival.32, 33
The multi-functionality and pivotal role that GSK-3 plays in many biological processes
and diseases has led to a high level of interest in GSK-3 as a treatment option for many diseases,
and the subsequent development of many GSK-3 inhibitors in the past decade.33 Many of these
inhibitors are being developed for the treatment of diseases including Alzheimer’s,39-41
diabetes,42 inflammatory disorders,42 and cancer.43 However, caution must also be heeded when
considering GSK-3 as a therapeutic target. While GSK-3’s involvement in a variety of processes
provides the opportunity to treat a variety of conditions, it also provides the opportunity to
interfere with a variety of processes possibly increasing the potential for undesired side effects.39
Understanding the effects of GSK-3 inhibition is difficult and depends on the specific context in
which the inhibitor is used.
Due to the therapeutic interest in GSK-3 inhibition and GSK-3’s complex nature, the
approach developed in this body of work was utilized to assess the effects of the selective GSK3ß inhibitor, 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8). TDZD-8 was one of
the first developed non-ATP competitive GSK-3ß inhibitors, and was synthesized as a potential
Alzheimer’s treatment.44 TDZD-8 binds to the active site of GSK-3ß inhibiting its activity

40

towards glycogen synthase-1 (GS-1) with an IC50 concentration of 2 µM.44 In rat models,
TDZD-8 has been shown to induce Ser-9 phosphorylation on GSK-3ß without altering Tyr-216
phosphorylation, but the precise mechanisms underlying TDZD-8’s inhibitory effects are
currently undetermined.36 Figure 2-1 shows the structure of TDZD-8.

Figure 2-1. TDZD-8

2.1.3 Approach Overview
The approach presented in this work extracts information pertaining to the cellular
network response to xenobiotics, such as TDZD-8, based on the levels of phosphorylated protein
obtained using the bead-based immunoassay platform discussed in chapter 1.

Euclidean

distances between the relative protein phosphorylation levels of all possible protein pairs are
calculated for each exposure condition, and used to describe the similarity in each pair of
proteins’ responses to the stimulation. Euclidean distances are simple metrics that have found
previous application in describing similar responses when analyzing biological networks.45-47
The approach presented is based on the postulation that a similar level of response for proteins
indicates that there exists a relatively close connection (direct or indirect) between the proteins in
the network and thus, the calculated Euclidean distances can be used to represent the “distance”
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between each pair of proteins in the network. These distances are then used as weighted edges
for graph theory analysis, and parameters that characterize the network are calculated.
Graph theory has proven to be a valuable mathematical modeling tool for gaining insights
into the topological organization of networks across various disciplines.45,

48-50

In graph

theoretical analyses, networks are depicted as graphs where objects in the network are
represented as nodes, and the pair wise relations between the objects are represented by lines
referred to as edges. Based on the connectivity of the graphs, statistical attributes that
characterize the structure and behavior of networked systems can be calculated.48-52 Since its
development in the 18th century, graph theory has found application in the study of many
networks including social, computer, economic, and, most recently, biological networks.45, 53-59
While advances in high-throughput data collection techniques have led to a rapid increase in the
application of graph theory analyses to the study of biological signaling networks, it has yet to be
used in toxicology, and specifically has never been applied to dose.
A common part of many graph theory analyses, including the analysis presented here, is
centrality analysis. Centrality analyses typically rank network elements using quantitative node
centrality parameters to identify interesting network elements.58

Node centralities allow

quantitative local measurement of the position of a node relative to other nodes in a network, and
can be used to infer the relative significance of a node in global network organization.1 The
equations used to calculate the many centrality parameters that exist reflect a particular node’s
network position in a variety of ways.

The calculations commonly describe a node’s

connectedness with other “neighbor” nodes. A path is a series of edges and nodes in a network
that can be used to connect one node to another. The determination of the shortest path
connecting a node and other nodes within the network is a common component of many node
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centrality calculations. The shortest path is the shortest possible sequential series of edges that
can be utilized to connect two nodes to each other. When edges are not weighted, the shortest
path length is equal to the number of edges connecting two nodes. When edges are given
weightings that describe the strength of the connection between nodes, the shortest path is the
shortest possible summation of the edge weight values assigned to the edges connecting two
nodes. High centrality scores typically indicate that a node can reach other nodes via relatively
short path lengths or that a node is frequently passed through in the shortest paths connecting
other nodes.60
In biological analyses, centrality parameters are most commonly used to identify proteins
that are functionally important to biological processes.58 In this chapter, centrality analysis was
used to identify key proteins involved in the MOA of a xenobiotic. This differs slightly in
comparison to traditional biological centrality analyses in that it does not focus on identifying the
most central proteins/nodes in the network, but monitors changes in the centrality of proteins to
determine which proteins are affected the most by xenobiotic exposure. In this chapter, the node
centrality parameter, radiality, was calculated for several intracellular proteins based on their
relative phosphorylation responses to increasing doses of TDZD-8.

Based on changes in

radiality, the proteins most affected by the xenobiotic were identified. The developed approach
maps cellular component responses based on networked relationships, providing an integrated
view of the effects exerted by xenobiotic exposure, and highlighting principal proteins involved
in the toxic mode of action.
2.1.4 Radiality
Radiality is a centrality parameter that was originally developed by Valente and Foreman
in 1998 for the analysis of social networks.61 Radiality is calculated based on the relationships
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between a node and its neighbors, but also includes information pertaining to the entire network
structure.61 In general, radiality indicates how integrated an individual node is with the rest of
the network. Therefore, radiality represents a suitable means to identify proteins that are most
greatly affected by a particular xenobiotic exposure.
Radiality is calculated by first computing the shortest paths, represented as
connecting all possible pairs of proteins in the network, where

and

,

represent the two

proteins for which the shortest path distance corresponds. The network parameter, diameter
, is then determined. The diameter is the maximum value obtained for the shortest path
between any two nodes in the entire network. Next, the value of each determined shortest path
are subtracted from the value of the diameter plus one. The resulting values for a particular node
to all other nodes in the network are then summed and divided by the total number of nodes ( )
in the network minus one to obtain the radiality value for that particular node. If a node has a
high radiality it is generally close to all other nodes in the network1. The radiality equation is
shown below.

Centrality parameters can be interpreted in various ways, depending on the specific
application of the analysis.62 Radiality as calculated in this work, concisely and simultaneously
describes each protein’s phosphorylation-mediated relation to all other proteins in the network.
Mechanistically, this means that a protein/node with low radiality is not highly integrated within
the network under a set of experimental conditions. A change in a protein’s radiality following
xenobiotic exposure provides evidence that the protein is affected by the xenobiotic and may be
a principal protein in the xenobiotics toxic MOA. In this work, radiality values were calculated
using the open source software platform Cytoscape along with a specially developed version of
44

the Cytoscape plug-in, CentiScape.63 The CentiScaPe plug-in was modified so that centrality
parameters were calculated using the Euclidean distance values as edge weights.
TDZD-8’s effects on 20 individual protein roles within the signaling network were
evaluated on an individual dose basis, and dose-response curves consisting of the radiality
parameter were constructed to describe changes in network connectivity.

The data driven

approach does not use any pre-existing knowledge of the xenobiotics structure or activity. It
captures the xenobiotic effects on a network level by describing perturbations in the relationships
between individual signaling proteins. The approach presented represents a complimentary
approach to those currently used to determine MOAs, because it can be used to evaluate virtually
any toxic compound from a network perspective in a relatively short time frame.
2.2 Experimental Procedures
2.2.1 Materials
4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione

(TDZD-8,

CAS

327036-89-5),

Dulbecco's modified Eagle's medium (DMEM), sodium pyruvate, D-glucose, L-glutamine, and
sodium bicarbonate were obtained from Sigma Aldrich (St. Louis, MO). HEPES, fetal bovine
serum, Ethidium homodimer-1 cytotoxicity kit, and penicillin-streptomycin were obtained from
Invitrogen (Carlsbad, CA). Human hepatocellular carcinoma-derived HepG2 cell line was
obtained from American Type Culture Collection (Manassas, VA).
2.2.2 Cell culture
HepG2 cells were cultured in DMEM, supplemented with 2 g/L D-glucose, 2 mM LGlutamine, 5 mM HEPES, 24 mM sodium bicarbonate, 1 mM sodium pyruvate, 10% fetal
bovine serum, 100 U/mL penicillin, and 100 mg/mL streptomycin. Cells were maintained in a
humidified atmosphere at 37°C, 5% CO2 and passaged at 80 % confluence.
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2.2.3 Dosing.
For plasma membrane degradation assays, cells were seeded into clear-bottom, blacksided 96-well plates at a concentration of 4 x 104 cells per well in DMEM without phenol red and
allowed to grow for 24 h before dosing. For multiplex phosphoprotein assays, cells were seeded
in 12-well plates at a concentration of 5 x 105 cells per well in DMEM without phenol red and
allowed to grow for 24 h. Following the 24 h growth period, medium was aspirated from wells,
and cells were challenged with 10, 20, 30, 40, 50, or 100 μM concentrations of TDZD-8. TDZD8 was prepared so that resulting well concentrations were <1 % DMSO.
2.2.4 Multiplex Phosphoprotein Assay
After 40 min or 10 h of exposure to increasing doses of TDZD-8 (10, 20, 30, 40, 50, or
100 µM), cells were washed with ice cold PBS and lysed. Total protein concentration was
determined using the DC Protein Assay (BioRad, Hercules, CA) according to the manufacturer’s
instructions. Protein phosphorylation was determined using the bead-based BioPlex suspension
array system (Bio-Rad, Hercules, CA), and lysates were prepared according to the
manufacturer’s protocol. Beads and detection antibodies against phosphorylated AKT (Ser473),
ERK1/2(Thr202/Tyr204, Thr185/Tyr187), GSK-3α/β (Ser21/Ser9), HSP27 (Ser78), IκBα
(Ser32/Ser36), JNK1/2 (Thr 183/Tyr185), MEK1 (Ser217/Ser221), p38MAPK (Thr180/Tyr182),
p53 (Ser15), and p90RSK (Thr359/Ser363), as well as cleaved PARP and activated caspase-3
were obtained from Bio-Rad (Hercules, CA).

Beads and detection antibodies against

phosphorylated BAD (Ser 112), CREB1 (Ser133), IGFR (Tyr1131), IRS1 (Ser636/Ser639),
EGFR (Tyr), MSK1(Ser212), p70S6 (Thr421/Ser424), AKT(Thr308), and p53(Ser46) were
obtained from EMD Millipore. Relative phosphorylation was calculated by normalizing to
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control, which only received dosing vehicle (1% DMSO). Experiments were performed in
triplicate.

2.2.5 Plasma Membrane Degradation Assay
To determine the relative level of plasma membrane degradation in HepG2 cells exposed
to increasing doses of TDZD-8, the ethidium homodimer-1 (EthD-1) assay was used. Twentyfour hours after seeding HepG2 cells, culture medium was removed and replaced with probecontaining culture medium (2 μM EthD-1). Dead control wells were exposed to 70% methanol,
and the plate was incubated for 30 minutes. Following the 30 minute incubation, cells were
challenged with increasing doses of TDZD-8 and placed in the plate reader immediately after
dosing. Fluorescent signal was obtained using the Infinite M1000 microplate reader (Tecan US,
Raleigh NC) with excitation wavelength of 530 nm and emission wavelength of 645 nm, read
from the bottom 40 min and 10 h following dosing.

Experiments were performed in

sextuplicate. Relative plasma membrane degradation was determined by normalizing to dead
control cells exposed to 70% methanol.

2.2.6 Data Analysis.
Statistical significance for relative phosphorylation and plasma membrane degradation
was assessed using two-way analysis of variance (ANOVA) with Bonferroni’s post-test. p <
0.05 was considered statistically significant. For plasma membrane degradation and relative
phosphorylation data, error bars reflect standard error of the mean (SEM). Euclidean distances
(E) were determined using SAS JMP (Carey, NC) and the equation
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Where v and ω represent the 2 protein nodes for which the distance between is being
calculated. All Euclidean distances were multiplied by 100 to facilitate network parameter
calculations with CentiScape. The node centrality parameter, radiality, was calculated based on
the Euclidean distance edge weights. There was no set threshold value for the existence of an
edge, and thus all distance values were used in the calculation of radiality. The node centrality
parameter, radiality (

is calculated using the equation

where ΔG is the network diameter (or the longest Euclidean distance pathway connecting any 2
nodes in the network), n is the number of nodes in the network, and

is the shortest

possible summation of Euclidean distance weighted edge lengths connecting node

to node

.

ΔG represents the compactness of the network, and can be interpreted as a relative estimate of the
ease of protein communication. When interpreting centrality from

, if the radiality of a

node, , is high, then the node is generally close to all other nodes in the network, and therefore
is considered central.1
2.3 Results
Forty min and 10 h TDZD-8 exposure time points were identified as points where critical
signaling events occur in a previous study by kinetically monitoring energy production processes
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in the cell, and were therefore utilized in this study.64 Relative plasma membrane degradation
following exposure to increasing concentrations (10, 20, 30, 40, 50, and 100 µM) of TDZD-8 for
these critical time points is shown in Figure 2-2. Two-way ANOVA comparing the relative
plasma membrane degradation in cells treated with TDZD-8 to control cells showed that there
were no significant differences in plasma membrane degradation following both 40 min and 10 h
exposure to 10 or 20 µM doses. Plasma membrane degradation increased significantly (p < 0.01)
in cells treated with 30 and 40 µM TDZD-8 for 10 h (compared to controls), but not in cells
treated for 40 min. Plasma membrane degradation increased significantly (p < 0.001) in cells

Relative Plasma Membrane Degredation

treated with 50 or 100 µM TDZD-8 for both 40 min and 10 h.

1.0
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0.8
0.6
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Dose TDZD-8 (M)

Figure 2-2. Relative plasma membrane degradation in response to exposure to increasing doses of
TDZD-8 for 40 min and 10 h.

Relative phosphorylation was determined for cells exposed to the same increasing
concentrations of TDZD-8 for 40 min and 10 h, and is depicted in Figures 2-3 and 2-4,
respectively. Simple inspection of the phosphorylation data does not concisely describe the
effects of TDZD-8 on the signaling network or provide a clear indication of its primary target.
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50

15

Dose TDZD-8
20.0 µM
10

30.0 µM
40.0 µM
50.0 µM
100.0 µM

Activated Caspase 3

p70S6K

p53 (Ser46)

MSK1

EGFR

AKT (Thr308)

Cleaved PARP

IRS1

IGFR

CREB

BAD

p90RSK

p53 (Ser15)

p38MAPK

MEK1

JNK

IkBa

HSP27

Histone H3

GSK3

0

ERK1/2

5

AKT (Ser473)

Relative Phosphorylation

10.0 µM

Figure 2-4. Phosphoprotein Response to TDZD-8 at 10 h.

To describe the networked response to treatment with TDZD-8, radiality was calculated
for each protein at each individual dose tested. Dose-response curves consisting of the radiality
values were constructed (Figure 2-5). Fluctuations in radiality values across the dosing range
indicate that the inhibitor treatment is causing the networked relationship between signaling
proteins to change.

A decreasing radiality value for a protein suggests it is losing

communication with the majority of proteins in the network. When using graph theory centrality
parameters, nodes are often ranked by their centrality values, or compared to the mean centrality
value for all nodes. Following 40 min exposure to TDZD-8, AKT (Ser 473), Cleaved PARP,
CREB, JNK, p38, ERK1/2, GSK-3α/ß, and p53 (Ser15) were the only proteins with radiality
values that were at least one standard deviation unit less than the mean for any of the doses
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tested. CREB, ERK1/2, and JNK radiality values were at least one standard deviation unit less
than the mean for 4 or more of the 6 doses tested. AKT, Cleaved PARP, p38, GSK-3, and p53
(Ser15) radiality values were only one or more standard deviation units less than the mean for
one dose. There were no proteins with radiality values more than one standard deviation unit
above the mean. Table 1 shows the mean radiality values for each dose and the corresponding
standard deviation.
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Figure 2-5. Radiality following 40 min TDZD-8 exposure.

Table 2-1. 40 min TDZD-8 mean radiality
Dose (µM) Mean Radiality Standard Deviation
10
543
74
20
365
69
30
361
61
40
482
91
50
287
49
100
468
81
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Following 10 h exposure to TDZD-8, ERK1/2, Histone H3, JNK, p38, p53 (Ser15), and
GSK-3 radiality values were at least one standard deviation unit less than the mean. Histone H3
radiality was only one standard deviation unit less than the mean for the 100 µM dose. All of the
other mentioned proteins had radiality values at least one standard deviation less than the mean
for at 3 or more of the doses tested. GSK-3 radiality values reached the lowest of any proteins in
the study for 10 h exposed cells, and GSK-3 was the only protein with radiality values more than
2 standard deviation units less than the mean. Figure 2-6 shows the radiality dose-response
curves for cells exposed to TDZD-8 for 10 h.
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Figure 2-6. Radiality following 10 h TDZD-8 exposure.

2.4 Discussion
The identification of toxic modes/mechanisms of response to xenobiotic exposure is
challenging in part due to the dynamic and complex networked nature of biological systems.
This is confounded by the fact that the existing interconnected relationships between the
numerous components that form biological network structures are poorly understood even in
normal undisturbed physiological states. There is a current need for approaches that are capable
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of rapidly characterizing a broad range of toxic mechanisms of response to virtually any
compound so that large numbers of compounds can be easily screened, and their potential impact
on human health may be assessed for both environmental and pharmaceutical purposes.
The developed graph theoretical approach was used to map cellular component responses
to toxic GSK-3 inhibition, and identify the principal proteins involved in the response
mechanism. By monitoring the centrality (radiality) of each protein in response to increasing
doses of inhibitor, key proteins whose role within the network changed, and are therefore likely
to be involved in the MOA, were identified. The obtained dose-response curves clearly indicated
GSK-3 as the primary target of TDZD-8 following 10 h exposure. In addition to identification of
GSK-3 as the primary target of the inhibitor, perturbations in the network roles of several other
signaling proteins were identified, indicating their possible involvement in the toxic MOA.
Following exposure to TDZD-8 for 40 min, AKT (Ser 473), cleaved PARP, CREB, JNK, p38,
ERK1/2, GSK-3, and p53 (Ser 15) were identified as proteins whose radiality was most greatly
affected. This agrees with research studies that have found GSK-3 inhibition to alter the activity
of CREB, p38, ERK1/2, JNK, p53, PARP, and AKT.31, 65-69
Recent research indicates GSK-3 as a central regulator of stress-response and survival
signaling that can promote both survival and death (depending on the cell type and experimental
conditions) through its influence on crosstalk between key signaling pathways including the
AKT, ERK1/2, JNK, and p38 pathways.30, 31, 33, 70 The results obtained here show that GSK-3
inhibition led to decreased cell viability in a cancer cell line agreeing with previous studies that
have found GSK-3 inhibition to be toxic in other cancer cell lines.71-73 In addition to identifying
proteins likely to be involved in the response mechanism, the approach presented also revealed
changes in protein roles that are suggestive of cell death progression. For example, significant

55

plasma membrane degradation was only observed following 40 min exposure to TDZD-8 at the
50 and 100 µM doses. ERK1/2 radiality showed a decreasing trend as the dose of TDZD-8
increased. ERK1/2 radiality was the 2nd highest of all proteins at the 10 µM dose, and at the 40,
50, and 100 µM doses, ERK1/2 was the protein with the lowest radiality. Following 10 h
exposure to TDZD-8, significant decreases in plasma membrane degradation were observed for
the 30, 40, 50, and 100 µM doses. Only GSK-3 had a lower summation of radiality values than
ERK1/2 across this dosing range.

It is well known that ERK1/2 promotes survival under

conditions of stress,74-77 and the dose-response curves constructed here suggest that a loss in
ERK1/2 communication with the network may be a contributing step in the mechanism of
toxicity for TDZD-8. JNK radiality tended to increase in response to increasing dose for both 40
min and 10 h exposure to TDZD-8, and JNK activation is a known death promoting mechanism
carried out in cells to counter the effects of ERK1/2 survival signaling.77-79 Thus, the increase in
JNK radiality and accompanied decrease in ERK1/2 radiality may play contributing roles in the
mechanism of toxicity for TDZD-8.
It has been shown that GSK-3 can facilitate phosphorylation of pro-apoptotic proteins to
promote apoptosis, or facilitate phosphorylation of anti-apoptotic proteins to neutralize their
action as inhibitors of apoptosis.70 Following 40 min exposure, CREB had the 2nd lowest
radiality value out of all proteins at the 100 µM dose of TDZD-8, and throughout the entire
dosing range CREB radiality was one of the lowest of all proteins. It is well established that
CREB activation is a survival promoting mechanism in cells exposed to stress.80, 81 The relative
phosphorylation data collected in this study show that CREB activation/phosphorylation is
increased at all doses tested, and yet cellular viability is compromised. The radiality values for
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CREB do reflect a loss in communication between CREB and the signaling network as a whole;
indicating that the network may not be responsive to CREB’s survival promoting efforts.
Following exposure to TDZD-8 for 10 h, p53 (Ser15), JNK, p38, ERK1/2, and GSK-3
radiality values were altered the most out of all of the proteins. GSK-3 radiality showed a
decreasing trend as the dose of TDZD-8 increased, reaching levels lower than any other protein,
and displaying a different trend from all other proteins, making it clear that TDZD-8 had the
greatest impact on GSK-3. This seems obvious knowing that TDZD-8 is a selective GSK-3
inhibitor, but had the identity of TDZD-8 not been known, the same conclusion could be drawn.
The presented network analysis approach was able to identify specific proteins affected by the
GSK-3 inhibitor following 40 min exposure, and was able to pinpoint GSK-3 itself as the main
target following 10 h exposure. Simple inspection of the phosphorylation dataset alone cannot
pinpoint these effects, and identification of protein targets would become even more difficult if
the number of proteins monitored were to increase (which is necessary to be able to determine
the mechanism of action for any unknown compound).
The approach presented here, as well as any study on signaling network responses, is
limited by the number of proteins for which data is available.11 Here the phosphorylation or
activation of 20 proteins was measured. In future studies, this data driven approach can easily be
applied to significantly larger data sets containing 100’s of proteins/nodes to provide a more
comprehensive and integrated description of toxic MOAs for virtually any xenobiotic without
reliance on any preexisting information. The presented approach is unique in that it describes
toxic MOAs from a network perspective, and reflects the coordinated cellular response to
exposure. It is advantageous in comparison to currently used approaches that utilize reference
compounds and libraries, because it can be used to evaluate any compound of interest.

57

Approaches relying on reference compounds are limited when it comes to characterizing MOAs
that involve multiple signaling pathways, as reference compounds are commonly designed to be
selective for specific pathways, and therefore, do not affect the network as broadly as other
xenobiotics. The results obtained here reflect the specific response of cells to a specific set of
experimental conditions. The utility of the presented approach in identifying the primary target
of a xenobiotic and identifying proteins involved in the xenobiotics MOA has been
demonstrated. This approach represents an attractive complimentary technique to those currently
used to determine MOAs that is simple, comparatively low cost, high-throughput, and can be
used to obtain toxicological information directly pertinent to human systems.
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Chapter 3
Characterization of Network Perturbations in Response to Inhibitor
Induced Mitochondrial Stress
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3.1 Introduction
Historically, toxicological assessments have been based on common endpoint evaluations
such as death, cancer, or an increase or decrease in levels of molecules associated with particular
biological processes. Modern toxicological evaluations have evolved to consider toxicity as a
perturbation of biological pathways or networks.1-4 As such, toxicity testing approaches are
shifting from common endpoint evaluations to pathway based approaches, where the degree of
perturbation of select biological pathways is monitored.3, 4 Pathway based approaches represent
a significant improvement to current toxicological assessments, but methods of analysis to
determine the inter-relationships between potentially affected pathways are needed to fully
understand the consequences of toxic exposure. This chapter demonstrates the utility of graph
theoretical analyses in assessing the toxicological effects of chemical exposure from a network
perspective. The network approach presented in chapter 2 is used to characterize the effects of
the mitochondrial complex I inhibitor, deguelin, on HepG2 cells on a dose-to-dose basis. The
approach depicts low dose perturbations in the balance between MAPK signaling pathways,
providing an informative and sensitive means of assessing toxicological effects on biological
systems.
3.1.1 Mitogen Activated Protein Kinase Crosstalk and Cell Death
The signaling proteins that have been most closely associated with chemical exposure
stress are the mitogen-activated protein kinases (MAPKs).3, 5-9 There are seven known separate
families of mammalian MAPKs, and the most extensively studied of these groups are the
ERK1/2, JNK, and p38 kinase pathways.10 ERK1/2 pathway activation is generally associated
with cell growth, proliferation, and survival, while p38 and JNK signaling pathways are typically
associated with stress responses and apoptosis.10 These three MAPK families have generally
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been thought to be involved in separate linear signaling cascades, since each MAPK is activated
by different upstream kinases, which are directed by distinct extracellular stimuli.9, 11 However,
it has been shown that crosstalk between these MAPK pathways does exist, and that the crosstalk
between these pathways may be crucial to their ability to coordinate certain cellular stress
responses including survival and inflammation.11-13

A network depicting the modular

organization of MAPK signaling is shown in Figure 3-1. It has been suggested that under
normal physiological conditions MAPK signaling pathways are linear with no crosstalk, but that
pathological conditions and stresses, such as exposure to xenobiotics, may drive crosstalk
between these pathways.14-17 The balance between ERK1/2, p38, and JNK signaling pathways
can push cells towards life or death.9, 15, 18 The ability to appropriately capture exposure-induced
alterations in the balance between distinct MAPK signaling pathways provides a unique view of
pathway based toxicity testing that can yield valuable insight into the underlying biological
response to chemical insults.

Figure 3-1. Modular organization of MAPK signaling pathways.
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3.1.2 Graph Theoretical Identification of Low-dose Network Perturbations
While advances in high-throughput data collection techniques have led to a rapid increase
in the application of graph theory analyses to the study of biological signaling networks, it has
yet find application in the field of toxicology, and specifically has never been applied to dose.
The determination of concentration ranges that lead to adverse health effects over time is
extremely important to toxicological assessments.19 This requires approaches that are capable of
assessing the effects that chemical exposures have on entire networks on a dose-to-dose basis.
Ideally, toxic effects should be identified before gross toxicological effects (with irreversible
consequences) are manifested. To do this, subtle alterations in normal cellular functioning
caused by low-dose exposures must be identified. Changes in the networked relationships
between signaling proteins (specifically MAPKs that influence cell life and death) are likely to
precede more direct toxic manifestations and represent an attractive early descriptor of the toxic
effects of exposure. The graph theoretical approach presented in this work can be used to
describe these networked relationships following exposure to low doses of toxic compounds.
In this chapter, HepG2 cells were exposed to increasing doses of the mitochondrial
inhibitor deguelin.20 Graph theory was used to describe the networked protein response at each
dose based on the levels of phosphorylation of 8 proteins (ERK1/2, JNK, p38, AKT, HSP27,
IκBα, p53, and p90RSK) related to mitochondrial stress. Two secondary inhibitors, SB202190
and SB202474 were dosed in combination with deguelin to further probe the network response.
The work presented in this chapter has been published in the American Chemical Society journal
Chemical Research in Toxicology.21
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3.1.3 Deguelin, SB202190, and SB202474
Deguelin was chosen as the inhibitor of interest in this study due to its ability to induce
mitochondrial stress, which is an important focus of many toxicity assays. Deguelin inhibits
Nicotinamide Adenine Dinucleotide (NADH): oxidoreductase (complex I of the electron
transport chain), AKT, and HSP90, and exhibits anticancer activity.22-26 Mitochondria have a
significant impact on cellular physiology due to their roles in ATP production, reactive oxygen
species (ROS) generation, Ca2+ homeostasis, and cell death.27,

28

Alterations in the signaling

networks involved in the regulation of these mitochondrial functions have been implicated as
contributing factors to many diseases including cancer.28-30 Further, mitochondria integrate a
multitude of signaling events, contribute to cellular death via mitochondrial membrane
permeability, and are common targets of both therapeutic and environmental xenobiotics.31-36
SB202190 and SB202474 were selected as secondary inhibitors (each dosed in
combination with deguelin) to further investigate the balance between the MAPK signaling
pathways following chemically induced stress. SB202190 inhibits both JNK and p38, while
SB20474 inhibits JNK but not p38. Both compounds exert the same effects on all of the other
proteins studied, and were chosen to allow comparison of just partial JNK inhibition to partial
JNK and p38 inhibition during deguelin exposure. The structures of deguelin, SB202190, and
SB202474 are shown in Figure 3-2.
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Deguelin

SB202190

SB202474

Figure 3-2. Deguelin, SB202190, and SB202474

3.2. Experimental Procedures
3.2.1. Materials
Deguelin was obtained from Sigma Aldrich (St. Louis, MO). SB202190, and SB202474
were obtained from Calbiochem (San Diego, California).

RPMI-1640, sodium pyruvate,

HEPES, L-glutamine, fetal bovine serum, and penicillin-streptomycin were obtained from
Invitrogen (Carlsbad, CA). HepG2 cells were obtained from American Type Culture Collection
(Manassas, VA).

Bio-plex beads, lysis buffer, antibodies, and reagents necessary for

determination of relative phosphorylation were obtained from Bio-Rad (Hercules, CA).
3.2.2 Cell culture.
HepG2 cells were cultured in RPMI-1640, supplemented with 1 mM sodium pyruvate, 5
mM HEPES, 2 mM L-Glutamine, 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100
g/ml streptomycin. Cells were maintained in a humidified atmosphere at 37C, 5% CO2 and
passaged at 80 % confluence.
3.2.3 Dosing.
Cells were seeded into clear-bottom, black-sided 96-well plates at a density of 4 x 104
cells per well and allowed to grow for 24 h. Media was then aspirated from wells, and cells were
challenged with varying concentrations of single and mixed compounds in fresh media.

73

Deguelin was prepared in dimethyl sulfoxide (DMSO) to concentrations of 0.001 µM to 100 µM.
SB202190 and SB202474 were prepared in DMSO to their manufacturer specified IC50
concentrations of 350 nM and 34 nM, respectively.
3.2.4 MTT Viability Assay.
After 400 min of exposure to single compounds or mixtures of compounds, cell viability
was determined using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT)
assay. This 400 min time point was chosen based on a previous study showing that changes in
cellular oxygen consumption point to critical signaling events occurring at 400 min of exposure
to deguelin.37 The MTT assay was performed according to the manufacturer’s protocol. The
assay is based on the reduction of tetrazolium MTT to colored formazan by metabolically active
cells, in part by the action of dehydrogenase enzymes, to generate reducing equivalents such as
NADH and Nicotinamide Adenine Dinucleotide Phosphate (NADPH). MTT reagent was added
to the wells of the microplate, and after two hours of incubation at 37C, intracellular formazan
crystals were solubilized with the provided detergent solution. Absorbance values were obtained
using the Safire2 microplate reader (Tecan US, Raleigh, NC) with a measurement wavelength of
570 nm and a reference wavelength of 700 nm, read from the bottom. From this, relative
viability was determined by subtracting the absorbance of blank wells (consisting of cell culture
media, the highest dose of the inhibitor being tested, all MTT reagents, but no cells) from all
treatments and controls. The ratio of the blank-corrected absorbance values for wells containing
treated cells relative to the wells containing controls (consisting of everything in the treated
wells, except the inhibitor) was determined.
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3.2.5 Bio-plex Multiplex Immunoassay
HepG2 cells were plated at 500,000 cells per well in 12-well tissue culture plates in
Dulbecco’s Modified Eagle Medium (DMEM) growth media (10% heat-inactivated FBS)
supplemented with 0.1% fatty acid-free bovine serum albumin (BSA) (Sigma, St. Louis, MO) for
24 h. Cells were then treated with increasing doses of deguelin (0.001, 0.01, 0.1, 1.0, 10, 100
µM) in 1% DMSO alone, or in binary combination with the IC50 concentrations of 350nM
SB202190 or 34nM SB20474. After an incubation period of 400 min, cells were lysed with lysis
buffer (Bio-Rad, Hercules, CA) supplemented with 500 µM phenylmethanesulfonylfluoride
(PMSF) (Sigma, St. Louis, MO) and phosphatase inhibitors (Bio-Rad, Hercules, CA). Total
protein concentration was determined using the DC Protein Assay (Bio-Rad, Hercules, CA)
according to the manufacturer’s instructions.

Beads containing antibodies against

phosphorylated ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), AKT (Ser473), HSP27 (Ser78), IκBα
(Ser32/Ser36), JNK (Thr183/Tyr185), p38MAPK (Thr180/Tyr182), p53 (Ser15), and p90RSK
(Thr359/Ser363) were obtained from Bio-Rad (Hercules, CA). Relative protein phosphorylation
was determined using the multiplexed bead-based assays and the Bio-plex suspension array
system according to the manufacturer’s instructions (Bio-Rad, Hercules, CA).

Relative

fluorescence values were calculated from the raw fluorescence levels after subtracting
background (no cells) and normalizing to control cells receiving only 1% DMSO.

All

experiments were performed in duplicate and error bars reflect the standard error of the mean
(SEM).
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3.2.6 Data Analysis.
Two-way ANOVA’s with Bonferroni’s post tests were performed using GraphPad Prism
version 5.03 for Windows, GraphPad Software (San Diego, California). Euclidean distances (E)
were determined with SAS JMP (Carey, NC) using the equation

Where v and ω represent the 2 protein nodes for which the distance between is being calculated,
and n represents the number of replicates for which phosphorylation data was collected. All
Euclidean distances were multiplied by 100 to facilitate network parameter calculations in
Cytoscape. There was no set threshold value for the existence of an edge, and thus all distance
values were used in the calculation of radiality.
(

The node centrality parameter, radiality

is calculated using the equation

where ΔG is the network diameter (longest path length connecting any 2 nodes in the network), n
is the number of nodes in the network, and

is the shortest possible summation of

Euclidean distance weighted edge lengths connecting node

to node . ΔG represents the

compactness of the network, and can be interpreted as a relative estimate of protein
communication. To interpret centrality from

: if the radiality of a node,

is high, then
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the node is generally close to all other nodes in the network, and therefore is considered central.38
Centrality parameters can be interpreted in various ways, and the interpretation often depends on
the specific application of the analysis.39

Radiality as calculated here, concisely and

simultaneously describes each protein’s phosphorylation mediated relation to all other proteins.
Mechanistically, this means that a protein/node with low radiality is not highly integrated within
the network, and is not highly central to network communication. Therefore the other proteins
are more central to this networks response for a given exposure condition. Radiality parameters
were normalized to the average radiality values for all proteins in the network, making proteins
with a radiality higher than 1, more central than average, and proteins with radiality lower than 1,
less central than average.

3.3 Results
3.3.1 Phosphorylation Response and Viability.
The relative phosphorylation levels (normalized to control cells that received less than
1% DMSO) for ERK1/2, JNK, p38, AKT, HSP27, IκBα, p53, and p90RSK were measured
following 400 min exposure to increasing doses (0.001, 0.01, 0.1, 1, 10, and 100 µM) of
deguelin alone (Figure 3-3A). The most exaggerated response to treatment with deguelin alone
was observed for p38 at the 10 µM dose. At the 10 µM dose of deguelin, p38 levels were 4.9 ±
0.1 times greater than controls. SB202190, a combination p38 and JNK inhibitor, was examined
and the relative phosphorylation levels for the 8 proteins were determined in cells treated with its
single IC50 concentration of 350 nM (Figure 3-3B). SB202190 was chosen due to the availability
of a negative control, SB202474. SB202474 is shown to exert the same effects as SB202190 on
cellular signaling, except for inhibition of p38.40-42 The 350 nM dose of SB202190 reduced p38
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phosphorylation to 0.61 ± 0.02 times that of control cells. Cells were exposed to the IC50 dose of
SB202474 (34 nM), and relative p38 phosphorylation levels were 1.2 ± 0.1 times that of control
cells (Figure 3-3B). Two-way ANOVA comparing the 8 proteins’ relative phosphorylation
responses to the IC50 doses of SB202190 and SB202474 shows that the only statistical difference
at p < 0.01 was for p38. The IC50 doses of SB202190 and SB202474 decreased relative JNK
phosphorylation to 0.416 ± 0.004 and 0.519 ± 0.004, respectively.

Relative IkBα

phosphorylation decreased to 0.33 ± 0.03 following exposure to the IC50 dose of SB202190 and
to 0.329 ± 0.001 following exposure to SB202474 at its IC50 concentration.
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Figure 3-3. Phosphorylation response to inhibitor treatments. HepG2 cells were exposed to
inhibitor treatments for 400 min. Shown are the phosphorylation levels relative to the vehicle
control (1% DMSO) as determined by multi-plexed bead immunoassay. Observed data points
represent the average of two replicates. Error bars represent the standard error of the mean.
Bars marked with (-) on figure B represent significantly different (p < 0.01) responses when
comparing SB202190 at its IC50 concentration to SB202474 at its IC50 concentration.
To probe the network response to deguelin, cells were exposed to increasing doses of
deguelin in combination with the 350 nM dose of SB202190, and relative protein
phosphorylation was determined (Figure 3-3C). The increased p38 phosphorylation observed in
response to deguelin alone was inhibited by SB202190 (Figure 3-3C) with the level of p38
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phosphorylation at the 10 µM dose of deguelin only reaching 1.1 ± 0.01 times that of control
treated cells. Cells were then exposed to increasing doses of deguelin in combination with 34
nM SB202474, and relative protein phosphorylation was measured (Figure 3-3D). In cells
treated with 10 µM deguelin in combination with 34 nM SB202474, the measured level of
phosphorylated p38 was 2.5 ± 0.1 times greater than control cells. Statistically significant
differences in protein phosphorylation responses of cells treated with each inhibitor combination
are listed in Table 3-1.
Table 3-1. Significant Differences in Phosphorylation Responsea
Dose Deguelin (µM)
Deguelin vs Deguelin + 350 nM
SB202190
AKT
ERK1/2
JNK
p38
HSP27
IkBa
p53
p90RSK
Deguelin vs Deguelin + 34 nM
SB202474
AKT
ERK1/2
JNK
p38
HSP27
IkBa
p53
p90RSK
Deguelin + 350 nM SB202190 vs
Deguelin + 34 nM SB202474
AKT
ERK1/2
JNK
p38
HSP27
IkBa
p53
p90RSK

0.001

0.01

0.1

1

10

***
**
***

***
**
***

***

***
***

***

**
***

***
**
***
***
***
**

**
***
***

***

100

***
***
**
**

***

***
***

***
***

***

***
***
***

***

***

***

***

***

**

***
***
***
***
***

***
***

**

**

***

(a) Statistically significant differences in relative protein phosphorylation when comparing
different inhibitor treatments. (***) indicates p < 0.001, (**) indicates p < 0.01, and (*)
indicates p < 0.05.
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Figure 3-4 depicts relative viability (normalized to control cells that received less than
1% DMSO) for cells treated with the inhibitors for 400 min. The only treatments that led to
statistically significant (p < 0.01) changes in relative viability in comparison to controls were for
cells treated with 34 nM SB202474 in combination with 10 or 100 µM doses of deguelin.
HepG2 relative viability was reduced to 62 ± 3% when treated with 10 µM deguelin in
combination with 34 nM SB202474 and 34 ± 3% when treated with 100 µM deguelin in

A

B

100

100

*
50

Deguelin Alone
SB202190 and Deguelin
SB202474 and Deguelin

*

0

% Viability

% Viability

combination with 34 nM SB202474.

50

0
0.001

0.01

0.1

1

10

100

SB202190 (350nM)

SB202474 (34 nM)

Dose Deguelin (uM)

Figure 3-4. Relative viability at 400 min as determined by MTT assay. (A) HepG2 cells were treated with
increasing doses of deguelin alone, increasing doses of deguelin in combination with a constant 350 nM
dose of SB202190, or increasing doses of deguelin in combination with a constant 34 nM dose
SB202474. Data are presented in terms of percent viability of the vehicle control (1% DMSO). Observed
data points represent the average of three independent experiments. Error bars represent the standard
error of the mean. Statistically significant (p < 0.01) changes in viability in comparison to control treated
cells are marked with (*). (B) Box-and-whisker plots for cells treated with SB202190 at its single IC50
dose, 350 nM or SB202474 at its IC50 value, 34 nM. Whisker ends represent the minimum and maximum
values.
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3.3.2 Euclidean Distances and Radiality
3.3.2.1 Deguelin Alone.
To obtain network edge weight values for graph theory analysis, Euclidean distances
between each pair of proteins were calculated based on their relative phosphorylation responses
(normalized to control cells that received less than 1% DMSO) to each individual dose of
deguelin. Table 3-2 shows the Euclidean distance values (in order of shortest distance to
longest), calculated based on the phosphorylation levels of proteins treated with increasing doses
of deguelin alone.

A low distance value means that the protein responses to the specific

conditions are similar, providing evidence of a connection or relationship between the two
proteins. Conversely, a high distance value means that the protein responses are not similar, and
that there is little evidence of a relationship between the two proteins. The distances between
ERK1/2, p38, and JNK were all relatively high (all distances being greater than the average
distance value) at the 0.001, 0.01, and 0.1 µM doses of deguelin. At the 1.0 µM dose of
deguelin, the distance between p38 and ERK1/2 decreased to less than the average protein
distance for all proteins, while the p38-JNK and JNK-ERK1/2 distances were well above
average. At the 10 µM dose of deguelin the distance between p38 and ERK1/2 increased and
was much greater than average, while the distance between JNK and ERK1/2 decreased to below
average. The p38-JNK distance remained high at the 10 µM dose. At the 100 µM dose of
deguelin, the distance between p38 and ERK1/2 decreased to less than average; the JNK-ERK1/2
distance was near average; and the p38-JNK distance was above average.

Three graphs

depicting the characteristics of the different network responses to the 3 inhibitor treatments at the
10 µM dose of deguelin are shown in Figure 3-5.
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Figure 3-5. Network graphs following exposure to a 10 µM deguelin dose of deguelin alone, in
combination with SB202190, and in combination with SB202474. Edge color and thickness are scaled to
represent the Euclidean distance between proteins. Red thick lines correspond to short distances and
green thin lines correspond to long distances. Node colors are scaled to represent the calculated
radiality for each node. Nodes with high radiality values are shown in red and nodes with low radiality
values are shown in green.

Table. 3-2 Deguelin Alone Euclidean Distances
Dose Deguelin
0.001 µM

0.01 µM

0.1 µM

1 µM

10 µM

100 µM

Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance
p90RSK ERK1/2 4.5

p53

AKT

18.2

HSP27 JNK

p90RSK AKT

26.6

p53

AKT

12.8

p90RSK AKT

HSP27 10.9
11.2

IKBa

p90RSK IKBa

20.0

IKBa

HSP27 13.3

1.5

HSP27 ERK1/2 11.2

IKBa

AKT

28.2

p53

IKBa

15.7

p90RSK IKBa

11.4

p90RSK AKT

22.6

IKBa

JNK

p90RSK AKT

19.7

p53

IKBa

30.2

IKBa

ERK1/2 23.3

IKBa

AKT

19.7

p90RSK ERK1/2 48.4

p38

ERK1/2 14.8

IKBa

AKT

27.4

p90RSK IKBa

53.6

19.8

IKBa

ERK1/2 61.2

JNK

AKT

30.3

p53

AKT

27.6

p53

AKT

56.6

HSP27 66.2

HSP27 AKT

31.8

JNK

ERK1/2 37.4

p90RSK p53

79.2

13.4

p53

IKBa

4.0

p90RSK IKBa

27.8

ERK1/2 AKT

IKBa

AKT

28.5

p90RSK ERK1/2 30.9

p53

p53

ERK1/2 37.7

IKBa

ERK1/2 39.0

ERK1/2 AKT

70.9

IKBa

AKT

35.6

HSP27 JNK

37.7

p38

36.2

ERK1/2 82.6

p90RSK p53

42.1

p53

p38

61.6

p53

p38

79.8

p53

IKBa

p90RSK IKBa

46.3

HSP27 JNK

92.2

ERK1/2 AKT

50.1

HSP27 p38

72.4

p53

AKT

97.8

p53

HSP27 45.4

p90RSK p53

47.0

p90RSK JNK

92.8

p90RSK AKT

54.4

p90RSK HSP27 83.0

HSP27 p38

112.3

p53

JNK

46.4

p90RSK JNK

55.5

JNK

107.1

IKBa

p53

112.5

p53

AKT

71.6

p90RSK ERK1/2 66.4

HSP27 ERK1/2 111.8

120.6

JNK

p90RSK HSP27 124.5

p53

HSP27 75.5

HSP27 AKT

HSP27 84.3

IKBa

76.7

HSP27 AKT

92.4

p90RSK p53

119.5

p90RSK AKT

HSP27 77.0

p90RSK p53

93.1

p38

AKT

129.0

p90RSK ERK1/2 144.7

p90RSK HSP27 75.2

IKBa

JNK

132.7

93.0

p53

IKBa

94.0

IKBa

p38

134.2

p90RSK JNK

ERK1/2 AKT

84.7

HSP27 AKT

150.1

HSP27 ERK1/2 94.0

p53

AKT

102.8

p90RSK p38

150.5

p90RSK HSP27 151.9

p53

JNK

92.5

p53

JNK

162.7

p90RSK HSP27 97.7

HSP27 ERK1/2 108.1

HSP27 AKT

163.1

p90RSK IKBa

155.7

HSP27 AKT

92.8

IKBa

HSP27 178.0

IKBa

p38

162.4

p53

ERK1/2 118.8

p53

ERK1/2 167.7

p90RSK p38

159.3

IKBa

JNK

93.6

JNK

ERK1/2 179.4

p53

p38

165.2

IKBa

p38

150.8

IKBa

HSP27 178.5

p90RSK p53

190.5

IKBa

ERK1/2 112.1

HSP27 p38

p38

AKT

168.6

p90RSK p38

152.0

p90RSK HSP27 184.0

ERK1/2 AKT

265.0

p53

ERK1/2 112.2

p53

HSP27 203.0

p38

ERK1/2 172.6

279.5

p53

HSP27 120.0

p38

JNK

IKBa

HSP27 120.2

p90RSK ERK1/2 235.5

IKBa

HSP27 p38

150.4

p38

AKT

162.3

p38

ERK1/2 195.3

p38

AKT

p90RSK p38

175.1

p38

ERK1/2 179.3

JNK

ERK1/2 214.5

JNK

ERK1/2 294.6

p90RSK JNK

AKT

67.8

AKT

312.6

ERK1/2 AKT

186.6
233.6

314.8

JNK

ERK1/2 289.6

HSP27 ERK1/2 231.7

HSP27 ERK1/2 296.0

HSP27 p38

JNK

ERK1/2 316.9

JNK

AKT

307.9

p90RSK JNK

262.8

IKBa

ERK1/2 300.3

p38

ERK1/2 320.2

IKBa

260.5

p53

JNK

327.0

p90RSK JNK

318.9

IKBa

JNK

274.8

p38

JNK

309.0

p38

JNK

345.1

p90RSK p38

IKBa

JNK

327.2

IKBa

JNK

323.1

JNK

AKT

285.3

HSP27 p38

310.4

p90RSK p38

386.2

p53

ERK1/2 314.5

JNK

314.9

ERK1/2 288.6
305.1

AKT

327.4

HSP27 JNK

396.1

p53

JNK

381.0

IKBa

p38

p38

AKT

404.8

p38

AKT

328.2

HSP27 JNK

402.4

p53

JNK

407.0

p38

JNK

406.5

p53

ERK1/2 335.2

IKBa

p38

432.2

IKBa

p38

356.4

p38

489.0

p38

JNK

468.3

HSP27 JNK

442.6

p53

p38

p53

p38

432.3

p53

p38

384.1

JNK

349.8
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Normalized radiality parameters for p38, ERK1/2, and JNK responses to deguelin alone
are depicted in Figure 3-6. Radiality concisely describes each protein’s simultaneous
phosphorylation mediated relation to all other proteins in the network, and was calculated as
described in the methods section (above). Fluctuations in radiality values indicate that the
inhibitor treatment is causing the network relationships between signaling proteins to change.
Radiality remains relatively constant in the dosing range of 0.001 to 0.1 µM for JNK, p38, and
ERK1/2 MAPKs, suggesting that these proteins signaling activities are not altered in this dosing
range. JNK radiality is lower than both p38 and ERK1/2 in the 0.001 to 0.1 µM range. At doses
of deguelin 1 µM and above, the normalized radiality parameters for p38, ERK1/2, and JNK
change: JNK radiality is increased while p38 and ERK1/2 radiality is decreased at the 1 µM
dose; JNK radiality remains high at the 10 and 100 µM doses, while p38 radiality remains low at
the 10 and 100 µM doses. ERK1/2 radiality is increased at the 10 µM dose to a level close to that
of JNK, and is slightly decreased at the 100 µM dose. The normalized radiality parameters for
AKT, IκBα, p53, p90RSK, and HSP27 remain relatively constant across the entire dosing range
(Figure 3-7).
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Figure 3-6. Normalized radiality dose-response curves for JNK, ERK1/2, and p38 responses following
exposure to deguelin alone. Radiality parameters are normalized to the sum of radiality parameters for
all measured proteins.
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Figure 3-7: Normalized radiality dose-response curves for all other protein responses following exposure
to deguelin alone. Radiality parameters are normalized to the sum of radiality parameters for all
measured proteins.
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3.3.2.2 Deguelin in Combination with SB202190.
Cells were treated with SB202190 in combination with deguelin to further probe the
alterations in p38, ERK1/2, and JNK network centrality observed in response to treatment with
deguelin alone, as initial results show that SB202190 partially inhibits both p38 and JNK (Figure
3-3B). Table 3-3 shows the calculated distance values for each pair of proteins in response to
treatment with deguelin in combination with SB202190. When cells were dosed with 350 nM
SB202190 in combination with the lower doses of deguelin (0.001 - 0.1 µM) the p38-ERK1/2,
JNK-ERK1/2, and p38-JNK distances were shorter in comparison to when cells were treated
with deguelin alone. At the 1 µM dose of deguelin, the distance between p38 and JNK was the
shortest distance between any of the 3 MAPKs (JNK, p38, and ERK1/2). At the 10 µM dose the
distances between all three MAPKs increased. At the 100 µM dose of deguelin, the distance
between p38 and ERK1/2 was much shorter in comparison to the JNK-ERK1/2 and p38-JNK
distances.
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Table. 3-3 Deguelin + 350 nM SB202190 Euclidean Distances
Dose Deguelin
0.001 µM

0.01 µM

0.1 µM

1 µM

10 µM

100 µM

Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance
p90RSK JNK

6.3

p90RSK AKT

27.5

p90RSK HSP27 27.0

JNK

AKT

18.3

p90RSK HSP27 26.6

p90RSK IKBa

16.5

IKBa

p38

39.2

JNK

AKT

27.7

IKBa

p38

32.9

HSP27 JNK

26.6

p53

IKBa

27.8

p90RSK p53

29.4

IKBa

ERK1/2 53.2

HSP27 JNK

33.8

p53

AKT

49.9

HSP27 AKT

42.8

HSP27 AKT

38.6

p53

IKBa

35.7

IKBa

p38

40.4

p90RSK JNK

52.4

HSP27 p38

60.4

p90RSK AKT

50.8

IKBa

AKT

38.2

p90RSK HSP27 67.2

p38

ERK1/2 51.6

HSP27 JNK

53.3

p38

69.7

p53

AKT

50.8

p38

ERK1/2 45.0

HSP27 ERK1/2 67.4

p90RSK JNK

55.1

IKBa

ERK1/2 61.1

p90RSK ERK1/2 70.8

p90RSK p38

59.9

p90RSK AKT

53.1

p38

HSP27 AKT

60.0

p38

ERK1/2 80.1

p38

AKT

IKBa

JNK

71.8

p53

AKT

72.3

ERK1/2 78.3

JNK

ERK1/2 109.2

p53

ERK1/2 81.5

HSP27 p38

74.6

HSP27 AKT

78.2

IKBa

AKT

78.2

p90RSK JNK

86.4

HSP27 JNK

66.4

ERK1/2 91.8

JNK

70.9

p90RSK AKT

95.5

IKBa

JNK

AKT

99.8

p90RSK HSP27 86.2

p90RSK AKT

113.7

p90RSK p53

JNK

ERK1/2 104.3

HSP27 ERK1/2 119.4

HSP27 AKT

129.0

p38

ERK1/2 93.6

p53

JNK

83.0

IKBa

HSP27 97.2

p90RSK ERK1/2 108.8

JNK

HSP27 ERK1/2 138.5

p53

p38

111.0

p53

HSP27 86.5

IKBa

JNK

100.7

IKBa

HSP27 112.3

ERK1/2 AKT

159.2

p90RSK p53

ERK1/2 AKT

143.9

p90RSK p53

101.6

p53

JNK

102.1

p53

AKT

137.3

p90RSK p53

163.8

p90RSK ERK1/2 153.9

HSP27 ERK1/2 151.4

p38

AKT

109.3

p53

HSP27 112.5

HSP27 p38

145.5

HSP27 p38

170.9

IKBa

JNK

163.8

JNK

JNK

AKT

111.9

p90RSK HSP27 112.9

HSP27 AKT

156.3

p90RSK ERK1/2 185.5

JNK

AKT

164.7

p90RSK p38

IKBa

HSP27 114.2

AKT

125.1

IKBa

JNK

157.4

p38

JNK

185.5

p53

HSP27 165.6

p53

HSP27 167.8

p90RSK IKBa

128.8

HSP27 JNK

197.3

p90RSK IKBa

161.7

p53

AKT

190.9

p38

JNK

188.5

p53

JNK

180.6

HSP27 JNK

149.6

HSP27 p38

221.7

p38

JNK

195.4

IKBa

HSP27 191.5

p53

JNK

190.9

p53

AKT

180.8

p90RSK JNK

152.0

p38

236.3

p90RSK p38

199.4

p38

AKT

209.1

IKBa

HSP27 198.6

p90RSK AKT

214.4

p53

p38

159.7

HSP27 ERK1/2 246.0

ERK1/2 AKT

204.1

IKBa

JNK

211.2

p90RSK IKBa

212.1

p90RSK HSP27 218.1

IKBa

p38

187.3

ERK1/2 AKT

246.9

p90RSK p53

232.4

p53

JNK

217.9

HSP27 p38

217.8

p90RSK JNK

221.3

p38

JNK

210.8

IKBa

p38

274.5

p53

JNK

237.0

p90RSK p38

234.7

p90RSK p38

234.0

IKBa

JNK

222.9

p38

ERK1/2 231.8

IKBa

ERK1/2 284.8

IKBa

AKT

257.1

IKBa

AKT

236.6

ERK1/2 AKT

p53

HSP27 289.2

p53

HSP27 245.3

p38

AKT

p90RSK IKBa

p53

ERK1/2 341.2

p53

ERK1/2 348.6

p53

IKBa

394.0

p53

p38

p53

p38

431.2

p53

IKBa

294.8

ERK1/2 134.8

144.9

87.2

ERK1/2 151.8
158.1

JNK

AKT

266.6

IKBa

AKT

227.2

p90RSK ERK1/2 289.9

p90RSK p38

p53

ERK1/2 298.2

IKBa

HSP27 234.8

HSP27 ERK1/2 306.3

p90RSK ERK1/2 298.0

IKBa

AKT

325.5

IKBa

p38

ERK1/2 AKT

340.4

p53

p38

p38

AKT

346.4

IKBa

ERK1/2 370.6

p53

ERK1/2 391.1

p53

ERK1/2 319.2

396.6

p53

IKBa

354.6

p53

IKBa

402.3

IKBa

ERK1/2 418.6

JNK

ERK1/2 339.2

426.7

p53

p38

378.2

p90RSK IKBa

441.3

JNK

ERK1/2 431.9

p38

JNK

263.3

292.1

Figure 3-8 shows the normalized radiality dose-response curve for p38, ERK1/2, and
JNK responses in cells treated with deguelin in combination with SB202190. The normalized
radiality values observed for deguelin plus SB202190 were relatively constant at the lower doses
of deguelin (0.001 – 0.1µM). ERK1/2 and JNK radiality values remained relatively constant
(ERK1/2: 1.06-1.12; JNK: 1.17.-1.20) from 0.001 to 1 µM and decreased at 10 and 100 µM. At
10 µM deguelin ERK1/2 radiality was 0.32, and at 100 µM it was 0.50. JNK radiality was 0.95
and 0.91 at the 10 and 100 µM doses, respectively. p38 radiality remained relatively constant
(0.82-0.94) from 0.001 to 0.1 µM deguelin with values less than both ERK1/2 and JNK. At the 1
µM dose of deguelin, p38 radiality increased to 1.17, a value greater than both ERK1/2 and JNK
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289.0
307.0

340.6

(1.06 and 1.15, respectively). At the 10 and 100 µM doses of deguelin, p38 radiality was 1.04
and 0.56, respectively. Figure 3-9 shows the normalized radiality dose-response curve for all
other protein responses in cells treated with deguelin in combination with SB202190.
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Figure 3-8. Normalized radiality dose-response curves for JNK, ERK1/2, and p38 responses following
exposure to deguelin in combination with 350 nM SB202190. Radiality parameters are normalized to
the sum of radiality parameters for all measured proteins.
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Figure 3-9. Normalized radiality dose-response curves for AKT, HSP27, IkBα, p53, and p90RSK responses
following exposure to deguelin in combination with 350 nM SB202190. Radiality parameters are
normalized to the sum of radiality parameters for all measured proteins.
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3.3.2.3. Deguelin in Combination with SB202474.
Cells were treated with SB202474 in combination with deguelin to further probe the
alterations in p38, ERK1/2, and JNK network centrality, as initial results show that SB202474
partially inhibits JNK, but not p38 (Figure 3-3B). Table 3-4 shows the distance values for each
pair of proteins in response to treatment with deguelin in combination with SB202474. The
distances between p38 and ERK1/2 were shorter than the JNK-ERK1/2 and p38-JNK distances
for the 0.001, 0.01, and 0.1 µM doses. The p38-ERK1/2 distance increased dramatically at the 1
µM dose of deguelin while the p38-JNK distance decreased dramatically. At the 1 µM dose of
deguelin, the p38-JNK distance was much less than the p38-ERK1/2 distance and the JNKERK1/2 distance. At the 10 and 100 µM doses, the distances between all three MAPK’s were
relatively high.
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Table 3-4 Deguelin + 34 nM SB202474 Euclidean Distances
Dose Deguelin
0.001 µM

0.01 µM

0.1 µM

1 µM

10 µM

100 µM

Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance Node 1 Node 2 Distance
p90RSK AKT

36.5

p90RSK AKT

16.6

IKBa

p38

33.3

JNK

AKT

20.0

p53

IKBa

4.9

p53

HSP27 11.4

p90RSK JNK

36.9

IKBa

p38

28.4

p38

ERK1/2 58.5

p38

JNK

39.1

IKBa

AKT

14.5

IKBa

AKT

19.0

HSP27 JNK

37.0

JNK

AKT

32.1

p90RSK HSP27 62.6

p38

AKT

48.1

p53

AKT

18.7

p90RSK p53

21.8

41.9

HSP27 JNK

67.3

HSP27 AKT

50.7

JNK

AKT

25.6

p90RSK IKBa

26.7

ERK1/2 57.0

p90RSK AKT

68.1

p53

ERK1/2 63.1

IKBa

JNK

27.0

p38

28.1

70.7

HSP27 AKT

27.8

p90RSK HSP27 31.7

HSP27 84.7

HSP27 JNK

30.0

p53

IKBa

45.2

p53

31.1

p90RSK AKT

45.5
47.0

p38

ERK1/2 52.0

p90RSK JNK

IKBa

p38

p38

IKBa

ERK1/2 58.5

p90RSK HSP27 73.7

p90RSK JNK

79.0

HSP27 JNK

JNK

AKT

HSP27 JNK

80.5

p53

54.9
70.4

78.0

AKT

p53

AKT

p90RSK HSP27 72.5

HSP27 ERK1/2 81.2

IKBa

ERK1/2 91.8

HSP27 ERK1/2 91.3

IKBa

HSP27 ERK1/2 107.1

p90RSK ERK1/2 106.3

p90RSK HSP27 36.4

IKBa

p38

HSP27 AKT

107.3

HSP27 AKT

84.0

HSP27 AKT

128.9

p53

AKT

117.2

IKBa

HSP27 40.8

IKBa

HSP27 51.9

HSP27 p38

121.4

HSP27 p38

136.6

JNK

ERK1/2 136.3

HSP27 45.6

p53

ERK1/2 82.0

HSP27 p38

89.0

JNK

p53

p38

125.6

p53

AKT

63.9

JNK

ERK1/2 127.8

p90RSK ERK1/2 153.8

p90RSK p53

136.7

p53

JNK

133.2

p90RSK AKT

62.3

HSP27 AKT

69.9

IKBa

HSP27 149.5

JNK

ERK1/2 157.1

JNK

AKT

139.9

HSP27 ERK1/2 144.8

p90RSK JNK

65.0

p90RSK p38

73.2

p38

JNK

IKBa

HSP27 162.9

HSP27 p38

164.7

p38

p90RSK IKBa

76.3

p53

p38

92.0

157.7

ERK1/2 160.1

p90RSK ERK1/2 160.9

ERK1/2 AKT

165.1

p90RSK ERK1/2 169.6

p90RSK p53

164.6

p90RSK p53

80.9

HSP27 p38

97.8

p53

AKT

178.2

p53

AKT

187.7

p38

JNK

184.0

ERK1/2 AKT

167.4

p90RSK p38

147.4

HSP27 JNK

120.3

IKBa

JNK

186.2

p53

JNK

189.7

p53

JNK

188.0

JNK

ERK1/2 179.6

p38

p53

JNK

129.9

p90RSK p38

193.9

p90RSK p53

203.0

IKBa

HSP27 197.9

IKBa

JNK

184.2

HSP27 p38

183.5

IKBa

JNK

137.3

ERK1/2 AKT

197.0

p90RSK p38

207.2

p53

HSP27 199.1

IKBa

AKT

193.4

p38

AKT

209.6

p90RSK JNK

140.0

p90RSK p53

214.4

p38

JNK

213.6

IKBa

JNK

214.7

IKBa

p38

216.0

p38

JNK

209.9

JNK

AKT

141.3

p90RSK IKBa

219.4

p38

AKT

219.6

p90RSK p38

226.7

IKBa

HSP27 222.9

IKBa

p38

223.7

p38

JNK

154.5

p38

AKT

228.1

p90RSK IKBa

234.5

ERK1/2 AKT

235.7

p90RSK HSP27 249.0

p53

p38

228.3

JNK

ERK1/2 328.7

p53

JNK

244.3

IKBa

JNK

239.1

p90RSK IKBa

259.8

p90RSK p38

263.0

p90RSK ERK1/2 315.1

p38

ERK1/2 336.1

IKBa

AKT

255.5

IKBa

AKT

246.5

p38

AKT

293.5

p90RSK AKT

273.6

HSP27 ERK1/2 350.8

ERK1/2 AKT

p53

HSP27 280.7

p53

HSP27 267.0

p53

ERK1/2 305.4

p90RSK JNK

285.4

JNK

IKBa

p53

ERK1/2 371.9

p53

ERK1/2 346.8

IKBa

AKT

326.8

p53

IKBa

305.9

ERK1/2 AKT

p53

p38

395.7

p53

p38

403.3

p53

p38

361.2

IKBa

ERK1/2 360.5

p53

IKBa

430.1

p53

IKBa

428.8

p53

IKBa

394.0

p90RSK IKBa

466.8

ERK1/2 168.4

ERK1/2 375.7

355.1

ERK1/2 370.2

377.5

p90RSK ERK1/2 394.0

IKBa

ERK1/2 391.3

HSP27 ERK1/2 400.3

p53

ERK1/2 396.0

p53

ERK1/2 402.4

Figure 3-10 shows the normalized radiality dose-response curve for p38, ERK1/2, and
JNK responses following treatment with deguelin in combination with SB202474. There is little
change in the radiality values for any signaling proteins for the 0.001, 0.01, and 0.1 µM doses of
deguelin (JNK: 1.13-1.18; ERK1/2: 1.07-1.08; p38: 0.94-0.99). JNK radiality remains relatively
constant all the way up to the 10 µM dose. At the 10 and 100 µM doses of deguelin JNK
radiality was 1.15 and 0.93, respectively. The 1 µM dose of deguelin indicates a point of slight
change for ERK1/2 and p38. At the 10 and 100 µM doses of deguelin, ERK1/2 radiality
decreased to 0.23 and 0.13, respectively. p38 radiality was 0.81 at the 10 µM dose of deguelin
and 1.11 at the 100 µM dose. Overall, the radiality curves for deguelin in combination with
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SB202474 are similar to the radiality curves for deguelin in combination with SB202190. The
curves do differ in the p38 and ERK1/2 radiality parameters at the 10 and 100 µM doses of
deguelin. This coincides with the viability curves for the 2 treatments, showing that treatment
with deguelin in combination with SB202474 leads to significantly decreased (p < 0.01) viability
at the 10 and 100 µM dose of deguelin while treatment with deguelin in combination with
SB202190 does not lead to significantly decreased viability at any doses tested. Figure 3-11
shows the normalized radiality dose-response curve for all other protein responses in cells treated
with deguelin in combination with SB202474.

Deguelin + SB202474
Normalized Radiality

1.5

p38
ERK1/2
JNK

1.0

0.5

0.0
0.001

0.01

0.1

1

10

100

Dose Deguelin (µM)

Figure 3-10. Normalized radiality dose-response curves for JNK, ERK1/2, and p38 responses following
exposure to deguelin in combination with 34 nM SB202474. Radiality parameters are normalized to the
sum of radiality parameters for all measured proteins.

91

Deguelin + SB202474
Normalized Radiality

1.5

AKT
HSP27
IKBa
p53
p90RSK

1.0

0.5

0.0
0.001

0.01

0.1

1

10

100

Dose Deguelin (µM)
Figure 3-11. Normalized radiality dose-response curves for AKT, HSP27, IkBα, p53, and p90RSK
responses following exposure to deguelin in combination with 34 nM SB202474. Radiality parameters
are normalized to the sum of radiality parameters for all measured proteins.

3.4. Discussion
With regard to toxicity testing, there is a current call to action for the modernization of
approaches that are used to quantitatively assess the health risks associated with chemical
exposure.1, 3, 43 Specifically, there is support for the integration of pathway based toxicity assays
into current methods to provide a better understanding of how even low-dose exposures perturb
biological processes in human cells and tissues.4 The major focus of this modernization has been
on monitoring the up regulation of proteins in specific pre-defined pathways.1, 4, 19, 43-45 It is now
understood that protein pathways are members of larger dynamic networks, that are highly
interconnected, and not always linear.46 One way of integrating pathway-based methods of
monitoring toxicity is to incorporate quantitative graph theory parameters that describe the
relevance or centrality of proteins within the network framework following chemical exposure.
Here, a simple data-driven approach was used to obtain such parameters, describing MAPK
signaling network perturbations that occur following chemically induced mitochondrial stress.
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Importantly, network parameters were assessed at each individual inhibitor dose, which allows
for a clear association between dose and perturbation response.
Graph theory was used to describe the balance between the traditionally distinct (i.e.
linear) ERK1/2, p38, and JNK MAPK pathways. Dose-response curves were constructed for
each protein where radiality was the response. Changes in the normalized radiality of MAPKs
indicate a shift in the balance of these MAPK pathways. The dose-response curves allowed
identification of shifts in individual protein centralities that accompany toxic exposures. This
approach is advantageous in comparison to other methods that investigate signaling, because it is
capable of revealing network perturbations that are induced by individual doses. An additional
advantage of this approach is that centrality parameters can be calculated based on weighted
edge values rather than the binary existence or absence of an edge that is typical of network
analyses, eliminating the need for set threshold values.
The results provide an integrated view of how low doses of deguelin perturb normal
MAPK signaling, and show that between the 0.1 and 1 µM doses of deguelin, there exists a
likely threshold dose where perturbation occurs. This is easily visualized by the dose-response
curves for p38, ERK1/2, and JNK radiality following exposure to deguelin (Figure 3-6). The
MAPK centralities remain relatively constant for doses lower than 1 µM, but at doses 1 µM and
higher there is a switch where JNK radiality becomes higher, p38 radiality decreases, and
ERK1/2 radiality varies. The ranked order of p38, JNK, and ERK1/2 radiality values remains
the same for the 0.001, 0.01, and 0.1 µM doses of deguelin, indicating that these doses do not
lead to changes in the relationships between the signaling proteins. The observed trends in the
dose-response radiality curves provide “snap shots” of signaling pathway alterations that occur
when cells perceive that an applied stress has reached a level in which a change in the
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mechanism of response to the stress is necessary. For all proteins other than ERK1/2, JNK, and
p38, radiality remained relatively constant across the entire dosing range (Figure 3-7), thus
supporting the concept of this type of analysis for the identification of perturbations to normal
network signaling. It is important to note that none of the doses of deguelin tested significantly
reduced HepG2 viability after 400 min of exposure (Figure 3-4A). Exposure to deguelin for 24 h
at doses higher than 1 µM does however lead to significantly decreased HepG2 viability.
Therefore, the analysis of the 400 min data revealed alterations in network signaling induced by
deguelin at a point where toxicity as determined by the MTT assay was not yet observed. This
demonstrates the utility of such data driven methods for assessing biological effects on a dose-todose basis, and determining significant doses capable of altering network signaling before
viability is compromised. The critical doses identified in this study may capture points where
cells are teetering between initiating death and promoting survival, and the application of graph
theory helps to illuminate shifts in the balance between MAPK pathways.
SB202190 and SB202474 were selected as secondary inhibitors (dosed in combination
with deguelin) to further investigate the balance between the MAPK signaling pathways
following chemically induced stress. Figure 3-3B confirms that SB202190 and SB20474 exert
the same effects on all of the proteins studied, except p38. Both compounds inhibit JNK, thus
allowing comparison of partial JNK inhibition to partial JNK and p38 inhibition during deguelin
exposure. Comparison of the Euclidean distances and radiality parameters obtained for cells
treated with deguelin in combination with SB202190 (Table 3-3) to cells treated with deguelin in
combination with SB202474 (Table 3-4) show similar results up to the 1 µM dose of deguelin.
Under both sets of conditions JNK radiality remains relatively high across the entire dosing
range (Figure 3-8 and Figure 3-10). At the 10 and 100 µM doses of deguelin, partial inhibition
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of p38 by SB202190 leads to a decrease in p38 radiality while SB202474 does not have this
same effect. ERK1/2 radiality decreases for both sets of conditions at these doses, but more so
with deguelin in combination with SB202474.

The only significant decreases in viability

observed for any of the treatments in this study were observed for the 10 and 100 µM doses of
deguelin in combination with SB202474 (Figure 3-4A).

Comparison of the dose-response

radiality curves for all three treatments (Figure 3-6, Figure 3-8, and Figure 3-10) shows that the
unique feature for deguelin in combination with SB202474 is that ERK1/2 radiality is extremely
low (effectively removed from the network) while p38 radiality is high. Treatment with deguelin
alone, or in combination with SB202190, leads to decreased radiality for p38 and comparatively
higher radiality values for ERK1/2. This indicates that for cellular viability to be decreased in
the cells tested; both p38 and JNK must maintain a central role within the network, while
ERK1/2’s centrality is simultaneously diminished.

ERK1/2 has previously been shown to

promote survival under conditions of stress when apoptosis is not favorable.47-49 When apoptosis
is favorable, both JNK and p38 signaling suppress the survival promoting activity of ERK1/2 via
crosstalk, thereby inducing apoptosis.15,

18, 50-52

The dynamic balance between these three

pathways has been shown to be a key determinant as to whether cells survive a threat or die.9, 15,
18

Specifically, the sustained activation of JNK and p38 signaling along with ERK1/2 pathway

inhibition has been shown to be required for the induction of apoptosis,18 and the results of this
study clearly support this notion. In addition to allowing the visualization of p38, ERK1/2 and
JNK signaling dynamics, the analysis also captured the p53 response to stress; p53 radiality
increases in a dose dependent manner in cells exposed to deguelin in combination with
SB202190 or SB202474 (Figure 3-9 and Figure 3-11, respectively). It is well known that p53 is
activated following a variety of cellular stresses playing a pivotal role in the stress response,53
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which provides further validity to the proposed analysis approach to characterize networked
cellular responses.

3.5 Conclusions
In agreement with previous studies, the results show that crosstalk between p38, ERK1/2,
and JNK signaling pathways is a complex and dynamic process.12,

15, 54, 55

The approach

presented was able to extract information reflecting the dynamic nature of MAPK signaling and
the central influence that the balance between ERK1/2, JNK, and p38 signaling crosstalk has on
whether or not cells maintain viability following chemical insult. Simple inspection of the
relative phosphorylation responses to each set of inhibitor treatments in Figure 3-2, as well as the
significant differences between these responses in Table 3-1, cannot provide such an integrated
description, thus demonstrating the utility of graph theory based methods for assessing
toxicological actions more broadly by reflecting a networked response. The work presented here
is well suited for identifying xenobiotic doses that induce changes in protein networks before
typical apical toxicological endpoints are reached. The calculated graph theory parameters
provide an integrated way of describing the degree of perturbation induced by specific doses of
toxic compounds in an in vitro human model by providing an informative and sensitive means of
assessing chemical effects on biological systems. These types of approaches have the ability to
highlight low-dose exposure induced changes at the molecular level, and may provide an
enhanced understanding of toxicological actions. In the future, the method presented in this
study could be expanded to include multiple exposure times, in addition to multiple doses. The
analysis of network changes over a sequential time series could also provide a means to monitor
network responses to xenobiotic exposures that contribute to adaptation. Additionally, network
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responses that lead to recovery/adaptation could be compared to responses that lead to death with
this approach. This along with an increased number of protein targets could provide a rich
depiction of the cells response to xenobiotic exposure, and represents a potential enhancement to
current methods used to study toxic mechanisms of action.
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Chapter 4
Tissue Trauma and Wound Healing Signaling Networks
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4.1 Introduction
In previous chapters, the network analysis approach developed in this body of work was
focused on investigating intracellular signaling. In this chapter the boundaries of the studied
network are expanded to encompass both extracellular and intracellular signaling providing a
wider biological scope. The analysis was used to investigate the networked response of muscle
tissue to traumatic injury.

The tissue response to traumatic injury is extremely complex,

involving coordinated efforts of many intracellular and extracellular proteins. Understanding
this response is a difficult task, and one that requires the use of approaches capable of integrating
multiple individual protein responses into easily interpreted biological meaning that describes
their collective functioning as a network.
In this chapter, signaling networks were investigated in a rat model of traumatic injury
where rats were subjected to a femur fracture. A dynamic network consisting of a wide variety
of signaling molecules regulates the muscle healing process. It is known that proteins within
networks that regulate the regeneration of muscle are spatiotemporally induced or repressed
following muscle injury.1

Yet, current understanding with regard to spatial differences in

molecular responses to tissue injury (especially networked responses) is limited, and so the
investigation was performed on rat muscle tissue samples collected from 3 different spatial
locations with regard to the injury site. As an initial investigation, spatial comparisons between
the levels of both extracellular and intracellular proteins at the 3 locations were made, and
proteins displaying spatial concentration relationships to the injury site were identified. The
presented network analysis approach was then used to describe the networked relationships of
the signaling proteins at each location. Cytokines were chosen as extracellular signaling proteins
to investigate due to their known roles as regulators of injury responses and inflammation.
Several intracellular proteins including MAPKs were also investigated.
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4.1.1 Cytokines
Cytokines are low molecular weight water-soluble signaling proteins that are secreted by
cells during inflammatory responses.2, 3 Once secreted, cytokines bind to specific receptors on
target cells to bring about change in the cell’s function. Cytokines can affect nearly any
biological process, and all cells, with the exception of red blood cells, can both produce and
respond to cytokines.4 Cytokine actions can be autocrine, paracrine, or endocrince by acting on
the cells that secreted them, on nearby cells, or on distant cells, respectively. Cytokines are
produced as needed, and their mRNAs are short lived.5 Pleiotropism is a hallmark of cytokines;
which have extremely variable and often contradictory activities ranging from inducing the
production of inflammatory mediators (e.g. ROS, nitric oxide, prostaglandins, and other
cytokines), cell recruitment, promotion of coagulant activity, assistance in antigen presentation,
initiating cell death, or inducing growth and repair.6 Following inflammation inducing events
such as infection or traumatic injury, an assortment of different cytokines are released by a
variety of cell types.

Each cytokine binds to a specific cell surface receptor initiating

intracellular signaling cascades (including MAPK signaling) that can affect gene expression.4
Some cytokines can also act as transcription factors that bind directly to DNA or function as
integral membrane proteins.4

Over the past 30 years cytokines have been investigated as

diagnostic, prognostic, and therapeutic agents with some success,4 but the ways in which these
diverse factors regulate complex cellular behavior remains poorly understood.
All inflammatory responses involve the production of a myriad of cytokines that can last
for periods of hours to weeks. Differing patterns of cytokine expression provide different gene
products responsible for specific cellular responses.5 Multiple cytokines can influence the same
signaling pathways. Some cytokines can signal through multiple receptors, and sometimes
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different cytokines can both act through the same receptor.7 The pleiotropic nature of individual
cytokines, overlapping actions of different cytokines, multiple cell types involved in cytokine
signaling, and the many different signaling pathways that emanate from single cytokine receptors
makes it difficult to understand how cytokines tailor their signaling to produce specific desired
responses.5, 8 Cytokines are potent, have high affinities for their receptors, and their receptors are
expressed in very low numbers per cell.2 It is likely that the number of different cytokine
receptors on a cell and the connectivity of its internal signaling networks are regulatory
mechanisms that contribute to the variable responses induced by cytokines. Different cell types
may respond differently to the same cytokine. Cytokines are important players in signaling
networks that span multiple cells making them essential to cell to cell communication under
periods of stress and injury. The diversity in cytokine signaling makes it difficult to understand
how cells and the tissues they make up function as dynamic networks capable of appropriately
responding to various environmental stresses.
4.1.2 Tissue Trauma, Wound Healing, and Cytokines
Cytokines act to promote tissue repair and homeostasis under periods of stress or injury.9
Wound healing is an evolutionarily conserved, sophisticated process involving the coordinated
effort of several cell types. The stages of wound healing include inflammation, formation of new
connective tissue and blood vessels, reepithelialization, matrix formation, and tissue
remodeling.10 This complex process is executed and regulated by the spatiotemporal actions of
cytokines and the complex signaling networks they form through their receptors and downstream
intracellular proteins.9-11
Cytokines may have local effects or initiate systemic changes following injury.3,

12

Immediately following tissue injury the local production of cytokines increases drastically.
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Cytokines are produced by both infiltrating and resident cells.13 Injured cells release cytokines
to achieve various outcomes including the recruitment of other cell types to the injury location.10,
14

Cells such as keratinocytes, firbroblasts, endothelial cells, macrophages, and platelets migrate

and infiltrate the wound area where they proceed to proliferate and differentiate aiding in the
removal of bacteria and tissue debri, the formation of new tissue, and the closing of the wound.10,
11, 14

cells.

Some cytokines serve as growth factors promoting the proliferation and differentiation of
Numerous studies have shown that the tissue response to injury involves variable

fluctuations in heterogeneous populations of cytokines in both space and time.3, 10, 12, 14-25 The
success of wound healing depends on the complex integration of the extracellular signal inputs
from cytokines.9, 10 How these variations in cytokine concentrations cause cells to respond in a
specifically regulated manner to carry out the wound healing process remains to be elucidated.

4.1.3 Muscle Tissue Injury
Skeletal muscle plays a central role in both motility and whole-body metabolism.
Skeletal muscle is the most abundant tissue in the human body,26 and is primarily composed of
elongated, parallel-running, multinucleated contractile muscle cells referred to as myofibers.27
Myofibers are heterogeneous with respect to size, metabolism, and contractile function.26,

28

Uninjured postnatal muscle cells are remarkably adaptable, constantly sensing and responding to
changes in the metabolic and functional demands of the organism.16 The number of myofibers
can increase or decrease throughout life with muscle growth, hypertrophy, or atrophy.27 In
response to physiological and pathological signals, muscle tissue remodels the biochemical,
morphological, and physiological states of individual muscle cells through the activation of
multiple intracellular signaling pathways that culminate in the activation or repression of a
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myriad of genes.16 The plasticity of muscle tissue is exemplified by the loss in muscle mass that
occurs under periods of disuse, the ability to regenerate this mass when normal activity is
resumed, and the ability of muscle to grow as functional demand increases.29 Skeletal muscle
cells can actively participate in local immune reactions.30 Myofibers and myoblasts express
cytokine receptors, and are capable of producing cytokines influencing the course of
inflammation.13,

23, 31, 32

A growing body of evidence suggests that, in addition to

immune/inflammatory responses, cytokines also influence normal physiologic functions of
skeletal muscle cells including anabolic and catabolic processes and apoptosis.11, 13 Therefore,
cytokines play an important role in muscle homeostasis, disease pathogenesis, and injury
responses. Despite the importance of cytokines as regulators of skeletal muscle function, there
are many gaps in our understanding of how cytokines affect muscle function under normal,
injured, and pathogenic circumstances.11 Understanding the mechanisms involved in modulating
skeletal muscle phenotypes is necessary to improve the treatment of muscular diseases, and to
understand the changes that muscle tissue undergoes in response to traumatic injury.
Inflammatory responses can be induced by a wide spectrum of injury severities in muscle
tissue ranging from overexertion to traumatic injury. Adult skeletal muscle has a remarkable and
unique capacity for regeneration following injury.25

Traumatic muscle injury initiates an

extensive and rapid repair process consisting of degeneration, inflammation, regeneration, and
fibrosis that takes place at the tissue, cellular, and molecular levels.24, 25, 33 Muscle healing is a
delicate balance between regeneration of normal muscle and formation of scar tissue, where the
inflammatory response can be both beneficial and damaging. If fibrotic tissue develops during
the healing process, the muscle’s function may become limited.24 Only a small number of
immune cells reside within intact skeletal muscle.33 Muscle injury causes the release of normally
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cytosolic molecules which can initiate the release of cytokines and rapid invasion by
inflammatory cell populations that can last for days to weeks while repair, regeneration, and
growth occur.11, 31, 33
Muscle growth and injury-induced regeneration in muscle is dependent on postnatal
muscle stem cells called satellite cells.25, 34 Satellite cells reside in an isolated microenvironment
between the thin sheet of membrane lining the surface of muscle (basement membrane) and the
cell membranes (sarcolemma) of individual myofibers.35 Following tissue damage the normally
quiescent satellite cells become active and migrate, proliferate, and differentiate to aid in repair
and regeneration.24, 33 Satellite cells differentiate to form mononucleated myoblasts which then
fuse together to form multinucleated myofibers.33

In addition, satellite cells can also

differentiate to form bone or fat cells.33 The regeneration process is heavily reliant on the
dynamic interplay between satellite cells and the structural and biochemical cues emanating from
their local molecular environments.36,

37

Immune cells and soluble factors such as cytokines

recruited to injured muscle tissue constitute a transient local environment for satellite cells.38
Satellite cells and immune cells can attract each other through cytokine secretion. Satellite cells
have been demonstrated to secret cytokines such as IL-6 and TNF-α to facilitate immune cell
infiltration and function.39 Immune cells in turn secrete factors that help satellite cells escape
from their sequestered compartments and promote satellite cell proliferation.40 Throughout
regeneration, the collaborative behaviors of satellite cells and other cells are heavily influenced
by changes to their local molecular environments.25, 31, 33 It is clear that these spatial differences
in the molecular environment of the various cells involved in the wound healing process is a key
aspect of wound healing process, warranting further investigation until a complete spatial
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mechanistic understanding of the complex molecular mechanisms that underlie skeletal muscle
healing is achieved.
As stated before, the response of skeletal muscle to traumatic injury is a complex,
highly coordinated process that relies on precise spatial and temporal regulation. Cytokine
responses have been extensively studied as important mediators of the response to trauma,20, 41
and MAPKs are recognized as being key to stress responses influenced by cytokine signals.5
The understanding that inflammatory cytokine responses can be both damaging and beneficial
has led to the use of both cytokine suppressing agents and cytokines themselves as
pharmacological treatments even without a thorough mechanistic understanding of cytokine
signaling.12 The immediate challenge is to advance the current understanding of the networked
relationships between the heterogeneous cell populations and molecules that coordinate the
injury response in complex and dynamic in vivo environments. In this chapter, the network
analysis approach developed in this body of work was used to integrate experimental data
obtained from injured muscle tissue, and map the complex network responses involved in the
tissue response to trauma.

4.2 Experimental Procedures
4.2.1 Animals
Adult male Sprague-Dawley rats were housed individually with a 12:12 light/dark cycle
with ad libitum access to standard rat chow and water. Four time points were studied with 3
replicates each (N = 3) for a total of 12 rats for the study. All procedures were performed under
the guidelines approved by the West Virginia University Animal Care and Use Committee.
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4.2.2 Femur Fracture
After adequate anesthesia all animals were subjected to a standardized femur fracture on
one leg using a custom designed tool in which a weight is dropped in a consistent fashion onto
the mid-shaft of the rat’s thigh.42 This tool delivers a calculated force of 104.80 Newtons,
generating a reproducible femur fracture and associated soft tissue injury.42 Buprenorphine SR
was pre-operatively administered subcutaneously as an analgesic providing 72 hour pain relief.
Rats were anesthetized intraperitoneally with Ketamine (80-90 mg/kg) and Xylazine (10-15
mg/kg). This combination of analgesic and anesthetics has previously been identified as the best
combination for avoiding significant modulation of cytokine responses in a rat model.43
Additionally, analgesics and anesthetics were injected into the scruff on the back of the rat’s
neck, thus there was an equal distance between the injection and both legs. An incision was
made to visualize the fracture. A hole was drilled into the proximal femur to allow a 0.045 inch
Kirschner wire (K-wire) to be inserted down the intramedullary canal to fix the fracture. The
incision was closed starting with the fascia and then using a stainless steel suture on the skin.
Rats were subcutaneously administered Yohimbine (2 mg/kg) post-operatively to reverse the
Xylazine and were closely observed during recovery for signs of distress.
4.2.3 Sample Preparation
Three rats were sacrificed at each of 4 time points (0, 6, 24, and 168 h post-fracture).
Rats were anesthetized intraperitoneally with Ketamine (80-90 mg/kg) and Xylazine (10-15
mg/kg). One cc of Euthasol was then administered via intracardiac puncture. Muscle tissue was
then harvested from the following 3 locations: at the site of the fracture, 1.0 ± 0.2 cm away from
the site of fracture, and from the leg opposite to the fractured leg. Figure 4-1 illustrates the
sampling locations. Samples were immediately rinsed with ice cold phosphate buffered saline
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(PBS), snap frozen, and stored at -80°C. Protein extraction was achieved using methods adapted
from those of Hulse et al.44 Samples were ground cryogenically and then lyophilized. For
analyses, 2-3 mg of lyophilized tissue sample was thawed for 10 min at 4°C in cell lysis buffer
(Bio-Rad, Hercules, CA) containing 20 mM phenylmethylsulfonyl fluoride (Sigma, St. Louis,
MO). Thawed samples were then vortexed for 1-3 sec, and homogenized with 3 rapid pulses
using an ultrasonic dismembrator. Samples were vortexed again for 1-3 sec and centrifuged at
5,000 x g for 5 min at 4°C. The supernatant was collected and total protein concentration was
determined using the RCDC protein assay (Bio-Rad, Hercules, CA) according to the
manufacturer’s instructions. Absorbance values were determined using an Infinite M1000 plate
reader (Tecan, Raleigh, NC).

Figure 4-3. Sampling locations following femur fracture. Muscle and vessel samples were obtained from
three different locations: (A) directly at the fracture site (B) 1 cm away from the fracture site (C) from
the opposite un-injured leg.

4.2.4 Analyte Measurement
Sample homogenates were diluted to a total protein concentration of 900 µg/ml with
sample diluent (Bio-Rad, Hercules, CA), and assayed for the cytokine targets, GM-CSF, IL-1a,
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IL-1ß, IL-2, IL-6, MIP-1a, and TNF-a, using the Bio-Plex Pro multiplexed magnetic bead-based
immunoassay reagent kit containing magnetic antibody coated beads with the Bio-Plex 200
suspension array system and Pro II Wash Station (Bio-Rad, Hercules, CA) according to the
manufacturer’s instructions. The cytokine targets VCAM and ICAM were assayed using the
Procarta multiplexed magnetic bead-based immunoassay reagent kit with the Bio-Plex 200
suspension array system and Pro II Wash Station (Bio-Rad, Hercules, CA) according to the
manufacturer’s instructions. Phosphoproteins were assayed using the Bio-plex phosphoprotein
kit containing polystyrene, non-magnetic antibody coated beads specific for the following targets
phosphorylated at the indicated amino acid residues: Akt (Ser472), c-Jun (Ser63), CREB
(Ser133), ERK1/2 (Thr202/Tyr204, Thr185/Tyr187), GSK-3α/ß (Ser21/Ser9), HSP27(Ser78),
JNK (Thr183/Tyr185), MEK1 (Ser217/Ser221), NF-kB (Ser536) p38 (Thr180/Tyr182), p70S6
(Thr421/Ser424), p90RSK (Thr359/Ser363), STAT2 (Tyr689), STAT3 (Tyr705). The relative
abundance of total protein was determined using a Bio-plex kit containing polystyrene, nonmagnetic antibody coated beads specific for Akt, c-Jun, CREB, ERK1/2, HSP27, JNK, MEK1,
p38, and p90RSK.
4.2.5 Statistical Analysis.
Data were analyzed using Prism 5 (GraphPad, San Diego, CA). Protein abundances were
compared based on the blank subtracted intensity of the relative fluorescence intensity (RFI)
measured for each antibody-coated bead.

Two-way analysis of variance (ANOVA) with

Bonferroni’s post test was used to determine significant differences between each sampling
location and between time points. All fluorescence measurements were performed in duplicate.
Data are expressed as the mean ± standard error of the mean (SEM).
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4.2.6 Network Analysis
Radiality values were calculated using Cytoscape and the CentiScape plugin. To account
for the variable sensitivity in the detection of the different targets, relative fluorescent intensity
signals were normalized for each individual protein target based on the minimum and maximum
values observed for the particular target across all samples to range from 0 to 100% using Prism
5. The Euclidean distances between these normalized values were used as distance values for the
radiality calculations performed using Cytoscape as described in chapter 2.

4.3 Results
4.3.1 Spatial Relative Fluorescence Intensity Comparisons
The spatial cytokine response data for IL-6, IL-1α, IL-1ß, IL-2, GM-CSF, TNF-α, and
MIP-1α have been published in the journal Cytokine.45
4.3.1.1 Cytokine Spatial Response Comparisons
Figure 4-2 shows the relative fluorescence intensity (RFI) values obtained for the assayed
cytokines at each sampling location at each of the four time points. Comparisons between the
RFI for each individual analyte at different locations were performed using 2-way ANOVA with
Bonferroni’s post test, and significant differences are indicated on Figure 4-2. Statistically
significant (p < 0.05) differences in RFI values when comparing the different sampling locations
were observed in samples taken immediately following the femur fracture (0 h time point) for
IL-2, TNF-a, MIP-1a, and ICAM. For samples taken 6 h following the injury statistically
significant differences in RFI values at the different physical locations were observed for IL-1ß
and IL-6. For samples taken 24 h after the femur fracture, the only significant difference
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between the sampling locations was in IL-1ß associated RFI. The only statistically significant
difference in RFI values for samples taken 168 h after the femur fracture was in VCAM levels.
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Figure 4-2. Cytokine associated RFI following femur fracture.
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4.3.1.2 Phosphoprotein Spatial Response Comparisons
Figures 4-3 and 4-4 show RFI values obtained for the assayed phosphoproteins at each
sampling location and at each time point. Statistically significant differences (p < 0.05) in RFI
values were observed across the 3 locations sampled for many of the assayed proteins, and these
significant differences are indicated in Figures 4-3 and 4-4. For samples collected immediately
following the fracture (0 h time point), RFI was significantly higher in the uninjured tissue
samples than in tissue samples taken directly from the fracture site and tissue taken 1 cm away
from the fracture site for phosphorylated Akt, c-Jun, ERK1/2, GSK-3α/ß, HSP27, and p70S6.
Phosphorylated CREB associated RFI values were also significantly different immediately
following femur fracture, but only when comparing samples from the uninjured leg to samples
taken from 1 cm away from the fracture. Significant differences in RFI values between sampling
locations were observed at the 6 h time point for phosphorylated Akt, GSK-3α/ß, and MEK1.
Significant differences in RFI values between sampling locations were observed at the 24 h time
point for phosphorylated p38 and GSK-3α/ß. Significant differences in RFI values between
sampling locations were observed at the 168 h time point for phosphorylated p38, p70S6, and
MEK1. No statistically significant differences in RFI for phosphorylated JNK, NFkB, p90RSK,
or STAT2 were observed when comparing any of the sampling locations at any time point.
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Figure 4-3. Phosphoprotein associated RFI following femur fracture.
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Figure 4-4. Phosphoprotein associated RFI following femur fracture.
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4.3.1.3 Total Protein Spatial Response Comparisons
Figure 4-5 shows total protein associated RFI values assayed at each sampling location
and at each time point. Statistically significant (p < 0.05) differences in total protein RFI values
were observed when comparing the different sampling locations for all of the studied time
points, and are depicted in Figure 4-5. In samples taken immediately following the femur
fraction, significant differences in Akt and ERK1/2 total protein associated RFI values were
found when comparing the different sampling locations. For samples taken 6 h following the
fracture, p38 was the only protein with significantly different RFI values between sampling
locations. Significant spatial differences for total MEK1 and p38 RFI values were observed in
samples taken 24 h after the femur fracture. The most significant differences between different
sampling locations for total protein associated RFI values were observed in samples taken 168 h
after the femur fracture. Akt, c-Jun, ERK1/2, JNK, and p38 all had significant spatial differences
in RFI values at this time point.
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Figure 4-5. Total protein associated RFI following femur fracture.
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4.3.2 Network Analysis
Radiality parameters were calculated for each of the 3 rats separately, and a mean
radiality values was calculated for all 3 rats. Radiality values were calculated separately for each
individual time point and location. Graphs depicting changes in mean radiality values over time
were constructed for each location.

Two additional analyses were performed, the first

incorporated protein responses at all 3 locations into the radiality calculation to give one radiality
value for the entire rat at each time point. This analysis is referred to as the across locations
analysis. The second analysis incorporated protein responses from all 4 time points into the
radiality calculation to give one radiality value for each location. This analysis is referred to as
the across time analysis. For all analyses, mean radiality values for each individual protein target
were compared to the mean radiality value obtained for all proteins targets ± the standard
deviation (SD). Two-way ANOVA with Bonferroni’s post test was used to determine protein
targets with significantly different (p < 0.05) radiality values at the same time points and
locations.
4.3.2.1 Radiality Comparisons at Fracture
Figure 4-6 depicts protein radiality values at the fracture site. For the network analysis
performed based on the response at the fracture site, immediately following the injury, IL-2’s
radiality was significantly lower than 14 other proteins. IL-2 was the only protein with a
radiality value that was significantly different from other proteins at this location and time point.
Immediately following femur fracture IL-2, GM-CSF, TNF-α, and phosphorylated STAT2 all
had radiality values less than the mean radiality value calculated for all proteins minus the SD.
For the network analysis performed based on the response at the fracture site 6 h
following the injury, IL-6’s radiality was significantly lower than 6 other proteins. IL-6 was the
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only protein with a radiality value that was significantly different from other proteins at this
location and time point. IL-6, VCAM and IL-1ß all had radiality values less than the mean
radiality value calculated for all proteins minus the SD.
There were no statistical differences in protein radiality values for the 24 h time point at
the fracture site. Phosphorylated p38, phosphorylated GSK-3α/ß, and total JNK all had radiality
values less than the mean radiality value calculated for all protein targets minus the SD. There
were no statistical differences in protein radiality values for the 168 h time point at the fracture
site.

Phosphorylated GSK-3α/ß, VCAM, total MEK1, IL-6, phosphorylated p70S6, and

phosphorylated STAT3 all had radiality values less than the mean radiality value calculated for
all protein targets minus the SD.
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Figure 4-6. Protein radiality values calculated based on protein responses measured in muscle sampled
at the fracture site. Proteins with radiality less than the mean observed radiality minus the standard
deviation are shown in color. Phosphorylated proteins are indicated with “p”. Total proteins are
indicated with “t”.
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4.3.2.2 Radiality Comparisons 1 cm Away from Injury
Figure 4-7 depicts protein radiality values 1 cm away from the fracture. There were no
significant differences in protein radiality values at the 0 h time point for the 1 cm away network
analysis. VCAM, total p38, IL-2, total JNK, and GM-CSF all had radiality values less than the
mean radiality value calculated for all protein targets minus the SD for the 0 h time point.
GSK-3α/ß had significantly lower radiality values in comparison to 9 proteins at the 6 h
time point. Phosphorylated GSK-3α/ß, GM-CSF, and phosphorylated p38 all had radiality
values less than the mean radiality value calculated for all protein targets minus the SD for the 6
h time point.
Phosphorylated p38 had a significantly lower radiality value in comparison to 27 other
proteins at the 24 h time point. Total p53 radiality was significantly lower in comparison to 2
proteins at the 24 h time point.

Phosphorylated GSK-3α/ß had a significantly lower radiality

value than 1 protein at the 24 h time point. Phosphorylated p38, phosphorylated GSK-3α/ß, and
total p53 were the only protein targets with radiality values less than the mean radiality value
calculated for all protein targets minus the SD for the 24 h time point.
GSK-3α/ß had a significantly lower radiality value in comparison to 21 proteins at the
168 h time point. Phosphorylated GSK-3α/ß, total MEK1, total JNK, and phosphorylated p38 all
had radiality values less than the mean radiality value calculated for all protein targets minus the
SD for the 168 h time point.
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4.3.2.3 Radiality Comparisons Uninjured Leg
Figure 4-8 depicts radiality values for the uninjured leg.

For the network analysis

performed based on the response in the uninjured leg, many of the radiality values for the
assayed proteins were significantly different from each other at the 0 and 6 h time points. Most
of these proteins with significantly different radiality values were cytokines.
At the 0 h time point phosphorylated p70S6, phosphorylated p38, phosphorylated
MEK11, phosphorylated HSP27, and phosphorylated NFkB radiality values were significantly
different than many of the other proteins targets. ICAM, TNF-α, VCAM, total p90RSK, and
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total CREB all had radiality values less than the mean radiality value calculated for all protein
targets minus the SD for the 0 h time point.
Phosphorylated CREB, IL- 1ß, ICAM, phosphorylated Akt, phosphorylated ERK1/2, and
GM-CSF all had radiality values less than the mean radiality value calculated for all protein
targets minus the SD for the 6 h time point.
Phosphorylated CREB, total MEK1, total JNK, phosphorylated p38, and IL-6 all had
radiality values less than the mean radiality value calculated for all protein targets minus the SD
for the 24 h time point.
Phosphorylated STAT3, TNF-α, total JNK, phosphorylated STAT2, and phosphorylated
MEK1 all had radiality values less than the mean radiality value calculated for all protein targets
minus the SD for the 168 h time point.
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Figure 4-8. Protein radiality values calculated based on protein responses measured in muscle sampled
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deviation are shown in color. Phosphorylated proteins are indicated with “p”. Total proteins are
indicated with “t”.

4.3.2.4 Across Locations Radiality Comparisons
To depict the global network response to the injury, radiality values were also calculated
across the sampling locations by including the protein responses from all 3 locations in the
Euclidean distance calculation. This results in 1 radiality value for each protein at each time
point. Figure 4-9 shows the radiality values calculated using normalized RFI values from all
three locations. Statistical analysis was performed to determine proteins with significantly
different radiality values at each time point.
At the 0 h time point, IL-2 was the only protein to have a significantly different radiality
value in comparison to the other proteins. At this time point, IL-2’s radiality was significantly
lower in comparison to 23 other protein targets. IL-2, TNF-α, GM-CSF, and total JNK all had
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radiality values less than the mean radiality value calculated for all protein targets minus the SD
for the 0 h time point.
At the 6 h time point IL-6 radiality was significantly lower than 13 of the other proteins,
and phosphorylated GSK-3α/ß was significantly lower than 17 of the other proteins.
Phosphorylated GSK-3α/ß and IL-6 were the only proteins with radiality values less than the
mean radiality value calculated for all protein targets minus the SD for the 6 h time point.
At the 24 h time point, phosphorylated p38’s radiality was significantly lower than 27 of
the other proteins, total p38 was significantly lower than 7 of the other proteins, and
phosphorylated GSK-3α/ß radiality was significantly lower than 3 of the assayed proteins.
Phosphorylated p38, total p38, and phosphorylated GSK-3α/ß all had radiality values less than
the mean radiality value calculated for all protein targets minus the SD for the 24 h time point.
At the 168 h time point, phosphorylated GSK-3α/ß was significantly lower than 29 other
proteins, and total MEK1 radiality was significantly lower than 13 other proteins.
Phosphorylated GSK-3α/ß and total MEK1 were the only proteins with radiality values less than
the mean radiality value calculated for all protein targets minus the SD for the 168 h time point.
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Figure 4-9. Across locations radiality. Radiality values were calculated based on protein responses at all
3 sampling locations. Proteins with radiality less than the mean observed radiality minus the standard
deviation are shown in color.

4.3.2.5 Across Time Radiality Comparisons
Radiality values were also calculated across the sampling time points by including the
protein responses from all 4 time points in the Euclidean distance calculation. This results in 1
radiality value for each sampling location. Figure 4-10 shows the radiality values calculated
using normalized RFI values from all 4 time points. Statistical analysis was performed to
determine proteins with significantly different radiality values at each location. At the fracture
site IL-2, IL-6, and VCAM radiality values were significantly (p < 0.05, p < 0.001, p < 0.05,
respectively) different from the mean. At the 1 cm away location, phosphorylated GSK-3α/ß,
phosphorylated p38, and total JNK radiality values were significantly different (p < 0.001, p <

130

0.001, p < 0.05, respectively) from the mean. For the uninjured leg phosphorylated GSK-3α/ß,
phosphorylated p38, and total MEK radiality values were significantly different (p < 0.001, p <
0.05, p < 0.001, respectively) from the mean.
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Figure 4-10. Across time points radiality. Radiality values were calculated based on protein responses
at all 4 time points. Proteins with radiality less than the mean observed radiality minus the standard
deviation are shown in color.

4.4 Discussion
4.4.1 Spatial Protein Responses to Injury
The current understanding of the molecular level changes that occur during tissue injury
and repair is extremely limited. Specifically, little is known regarding the spatial differences in
molecular responses following traumatic injury. The most well characterized aspect of the
response to traumatic injury is the regulatory role of cytokines. The temporal cytokine response
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to traumatic injury and other physical stresses has been extensively studied in various tissues and
experimental models.22,

46-53

Cytokine production reflects the degree of tissue trauma.3

Temporal changes in cytokine concentrations have been shown to correlate with negative early
post-trauma implications such as acute respiratory distress syndrome (ARDS), multiple organ
failure (MOF), wound failure, and mortality.49, 54-56 Temporal cytokine responses to traumatic
injuries have demonstrated utility as objective predictors of acute wound healing outcomes that
can assist surgeons in making appropriate surgical decisions with regard to procedural selection
and timing.49-53
Since the heavily studied temporal cytokine responses have shown promise as predictive
biomarkers beneficial to the treatment of traumatic wounds, knowledge of spatial differences in
molecular responses to injury may also be beneficial to the treatment of wounds. Previous
studies have determined that the local immune environment of traumatic injury sites differ in
cytokine concentration in comparison to systemically circulating concentrations,22 but the
relationship between tissue cytokine concentrations and physical distance from the injury site has
not been elucidated. If cytokines display spatial relationships to injury sites, they may be used as
quantitative descriptors of the state of different regions of tissue following traumatic injury. The
results obtained in this work identified the existence of spatial cytokine concentration gradients
in response to blunt trauma using a reproducible injury model.
The cytokines assayed showed significant spatial differences in concentration at all of the
studied time points with the majority of significant differences being observed during the early
response to injury (immediately following the injury and 6 h after the injury). Immediately
following the injury MIP-1a and IL-2 showed elevated levels at the injury site, and 6 h after the
injury, IL-6, IL-1ß, and MIP-1a levels were elevated at the injury site. Of all the cytokines
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assayed, IL-6 showed the strongest spatial relationship to the zone of injury. At the 6 h time
point IL-6 levels were significantly different at all 3 sampling locations. At this time point, IL-6
levels decreased as distance from the fracture increased suggesting that IL-6 could potentially be
used as a spatial biomarker of the zone of injury. IL-6 is well established as an important
modulator of the chain of events that follow traumatic injury, and has been related to negative
patient outcome following trauma.55

IL-6 has also been shown to induce satellite cell

proliferation.40 The IL-6 response observed in this work is in general agreement with previous
studies; Hauser, et al. showed that IL-6 levels peaked before 48 h and then decreased in softtissue hematoma sera of humans with high-energy bone fractures.22 Pape, et al. observed a peak
in circulating IL-6 levels 7 h after skeletal fracture surgery.52 They described IL-6 as a pivotal
marker of the response to blunt trauma, and demonstrate that increased levels are indicative of
surgical complications and adverse outcomes.52
In addition to cytokines, the spatial relationship of MAPKs to the injury site was also
investigated. MAPKs are involved in the signaling downstream of cytokine receptors, and the
production of some cytokines can be regulated by MAPKs.57 Tissue samples were analyzed to
determine if spatial differences in the levels of phosphorylated MAPKs also exist. Immediately
following the femur fracture 8 of the 14 MAPKs assayed had spatially different levels of
phosphorylated protein at the different sampling locations.

At this earliest time point

phosphorylated Akt, c-Jun, ERK1/2, GSK-3α/ß, HSP27, p70S6, and STAT3 levels were
significantly higher in the uninjured leg than in the samples taken at the fracture site and 1 cm
away. The phosphorylated levels measured in samples at the fracture site and in samples 1 cm
away from the fracture were not significantly different from each other for these 7
phosphorylated proteins. This indicates that the tissue at the fracture site has a similar response
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to the tissue 1 cm away with regard to these proteins. This also indicates that immediately
following injury phosphorylation activity generally decreases at the fracture site and 1 cm away,
as there were no instances where phosphorylated protein levels were higher at these two sites
than in the uninjured tissue. This decrease in phosphorylation may be due to loss of cellular
regulation over kinase activity that may arise as a result of the breakdown of the cellular
cytoskeleton leading to disruption of scaffold proteins that help facilitate kinase interactions and
loss of spatial kinase separation.58 The decrease in phosphorylation activity could also be due to
ischemia and impaired/injured mitochondria leading to reduced ATP availability which is
necessary for phosphorylation to occur.
Six h after the femur fracture only 3 of the 14 assayed proteins displayed spatial
differences in phosphorylated protein levels. These phosphorylated proteins were MEK1, GSK3α/ß, and Akt. Twenty-four h after the femur fracture, GSK-3α/ß and p38 were the only
phosphorylated proteins that showed significant differences between locations, and p38, MEK1,
and p70S6 were the only phosphorylated proteins with levels that were significantly different
when comparing the different sampling locations at the 168 h time point. Overall, these results
suggest that MEK1, GSK-3α/ß, Akt, p38, and p70S6 are likely to play key roles in mediating the
later tissue response to injury. Akt, p70S6, STAT3, and MEK1 have previously been implicated
as proteins important to cytokine signaling, specifically in IL-2 mediated signaling.8 GSK-3α/ß
is known to be an extremely important mediator of muscle tissue physiology,29 and p38 is a well
known responder to cytokines and many different types of stress.59-61
In addition to phosphorylated proteins and cytokines, the total levels (phosphorylated or
not) for some of the phosphoproteins were also measured. Immediately following the femur
fracture, only two proteins (Akt and ERK1/2) were found to have significantly different levels in
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total protein at the different sampling locations both having higher levels in the uninjured leg
than at the fracture site and 1 cm away. Only p38 levels were significantly different across
locations 6 h after the injury. p38 and MEK1 were the only proteins with significantly different
levels across sampling locations 24 h after fracture. The most spatial differences in total protein
levels were found 168 h after the injury with ERK1/2, p38, Akt, CREB and JNK all showing
spatial differences in total protein levels. All of the spatial differences observed at this time
point show increased total protein expression at the fracture site, reflecting phenotypic
differences in newly healed or grown tissue in comparison to undisturbed tissue in the uninjured
leg. Ischemia is known to activate MAPK signaling, and both ERK1/2 and p38 signaling can
activate CREB in response to stress.58
In summary, the protein levels measured indicate that IL-2 and MIP-1α may be key to
initiating the tissue response to injury. The most significant variations in cytokine levels across
locations are observed at the 6 h time point, and differences in total protein levels across
sampling locations are observed primarily 168 h after injury. Overall, the data indicates that
with regard to the proteins studied, immediately following injury, phosphoproteins may be the
most suitable biomarkers of the zone of injury, while 6 hours after injury cytokines are better
suited. This is the first study to analyze the levels of phosphorylated proteins in tissue samples at
different distances from a traumatic injury.

It provides evidence that the monitoring of

phosphorylated proteins could potentially be used as a spatial marker of the state of injured
tissue. These results demonstrate that spatial cytokine and MAPK gradients exist following
traumatic injury, representing potential biomarkers that may be used to define the ZOI.
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4.4.2 Network Response to Tissue Injury
The data presented here, as well as in other studies, have made it clear that cytokines are
essential mediators of the injury response.10,

12

Even with the multitude of existing data

describing signaling pathways downstream of cytokines, the means by which cells and tissues
integrate multiple cytokine signals to achieve desired responses is unclear.

MAPKs are

downstream responders to cytokine signaling and essential to stress responses. However, the
networked relationships between cytokines and MAPKs following traumatic injury remains
poorly understood.

The observed individual protein responses presented here demonstrate how

challenging it is to understand how multiple proteins function together when responding to a
stress as complex as traumatic tissue injury. The network analysis technique developed in this
body of work was applied to the individual cytokine, phosphorylated MAPK, and total MAPK
responses to provide an integrated view of how these multiple components function collectively
as a network in response to tissue injury. The analysis describes the network cohesiveness with
which each individual protein responds to the injury. A protein with low radiality is responding
to the injury in a different way than the majority of other proteins, and may be important to the
injury response in muscle. Comparison of the radiality values obtained at different time points
and sampling locations can reveal how protein network roles change in response to varying
degrees of perturbation, and assist in defining network relationships involved in muscle healing.
Figure 4-11 summarizes the network analysis results by mapping the time course of key proteins
to the tissue response at each location.
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p-GSK-3α/ß
t-MEK1

Figure 4-11. Schematic depicting important proteins identified at each time point and sampling
location. The depicted proteins each had radiality values less than the mean radiality value minus the
standard deviation of the mean.

STAT2 was the only phosphorylated protein identified by the analysis at the earliest time
point for any of the network analyses, including the across locations analysis. STAT proteins are
known as important downstream rapid responders of cytokine signals.62, 63 Research has shown
that STAT2 is required for early differentiation of satellite cells in injury-induced skeletal muscle
regeneration.34 For the network at the fracture site, IL-2 radiality had the lowest radiality of all
the proteins immediately following femur fracture. It is well known that IL-2 can activate STAT
proteins, and STAT proteins can actually dock onto the intracellular portion of the IL-2
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receptor.8, 62, 64 Simple inspection or statistical analysis of the raw phosphorylation data does not
provide any indication of such a relationship. The network analysis also identified IL-2 as an
important responder immediately following injury in the networks constructed 1 cm away from
the injury, in the across locations network, and in the across time points analysis at the fracture
site.
An additional known reaction that occurs immediately following injury is the release of
TNF-α which in turn stimulates the release of IL-6.3, 13 The network analysis at the fracture site
as well as the across locations network analysis identified TNF-α as an important protein
immediately following the injury, and IL-6 subsequently emerged as an important protein 6 h
following the injury for the fracture site analysis and across locations analysis. IL-6 is the main
cytokine responsible for inducing systemic changes known as the acute phase response.9,

65

TNF-α and IL-6 are well known regulators of muscle integrity,11, 13, 17, 26, 66 and have been shown
to function as inhibitors of myogenesis.67-70 During inflammatory responses, these two proteins
have been shown to inhibit repair processes, promoting protein degradation and the breakdown
of existing tissue.13, 26, 69, 70
Much of the network analysis results point to GSK-3α/ß phosphorylation activity playing
a significant role in the muscle tissue response to injury. This agrees with a growing amount of
evidence that implicates GSK-3α/ß as a central regulator of skeletal muscle plasticity.16, 29, 71-73
Phosphorylated GSK-3α/ß was identified as a key protein in the network analysis results 24 h
after the injury at the fracture site; in the network analysis results 1 cm away from the injury at
the 6, 24, and 168 h time points; in the across locations network analysis results at the 6, 24, and
168 h time points; and by the across time points analysis 1 cm away and in the uninjured leg.
GSK-3α/ß has been referred to as a “master regulator” of skeletal muscle, having an influence on
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atrophy, protein degradation, protein synthesis, and cell death in muscle cells.29 The results
obtained in this work show decreased phosphorylation of GSK-3α/ß on Ser-21/9 at the fracture
site in comparison to the uninjured leg at the 0, 6, and 24 h time points. It is important to note
that a decrease in Ser-21/9 phosphorylation on GSK-3α/ß corresponds to an increase in GSK3α/ß activity.29

Previous studies have also observed increased GSK-3α/ß activity

(phosphorylation on Ser-21/9) in burn injury induced atrophying muscle.71, 72 Pharmacological
inhibition of GSK3 with TDZD-8 has even been used to block burn induced muscle protein
breakdown.71 The network analysis approach was able to reflect the importance of GSK-3α/ß
activity to the complex network regulation of the tissue level response to injury based on
condition specific data.
GSK-3α/ß has been implicated as a downstream target of the Akt/mammalian target of
rapamycin (mTOR) signaling pathway following its activation during muscle remodeling.16 Akt
inhibits GSK-3α/ß activity directly by phosphorylating Ser-21 and Ser-9 on the α and ß isoforms,
respectively.73-76

At the 0 and 6 h time points both Akt phosphorylation and GSK-3α/ß

phosphorylation (measured on Ser-21 for GSK-3α and on Ser-9 for GSK-3ß) were significantly
less at the fracture site in comparison to the uninjured leg. Akt functioning is essential in skeletal
muscle for myogenesis and proper maintenance of muscle mass.26 The Akt signaling pathway
promotes protein synthesis to increase muscle mass partly through the simultaneous activation of
p70S6K and inactivation of GSK-3α/ß.16, 26 Attenuated Akt signaling results in increased GSK3α/ß activity (decreased Ser-21/9 phosphorylation) in skeletal muscle, which in turn contributes
to enhanced protein degradation.29 Akt phosphorylation is diminished in many muscular disease
states,16, 73 and a study by Bodine et al. demonstrated that both Akt and GSK-3ß phosphorylation
increase in rat models during compensatory muscle hypertrophy (growth and size increase).77
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While a study by Smith et al. found that reduced Akt activity was accompanied by reduced
phosphorylation of GSK-3ß in muscles with increased protein degradation.78

The results

presented in this work show that Akt activity decreases in response to the injury while GSK-3α/ß
activity increases, suggesting that the injured tissue is not attempting to synthesize proteins or
promote growth as much as the uninjured tissue. Taken together, the identification of IL-6 and
TNF-α as important proteins at the early time points as well as the decreased Akt and GSK3-α/ß
phosphorylation, suggest that at the early time points cellular efforts are directed towards
stopping growth and breaking down existing tissue.
Many of the network analyses pointed to p38 as an important protein in the injury
response. Phosphorylated p38 was identified as an important protein at the 24 h time point by all
of the network analyses (all 3 locations and across locations). Phosphorylated p38 was also
highlighted by the analysis 1 cm away at the 168 h time point and by the across time points
analysis 1 cm away and in the uninjured leg. Total p38 was highlighted by the 0 h, 1 cm away
analysis and by the 24 h across locations analysis. p38 is a known mediator of myogenic
differentiation.79-84 p38 is recognized as a necessary switch that turns on differentiation,79, 82, 84
with p38 activity having been shown to increase dramatically during myoblast myogenic
differentiation80, 83 and in injured human muscle.85 p38 activation has been shown to occur 1 day
after muscle injury and last as long as 10 days.17 The results obtained here align with this
previous study, with high p38 levels being observed 24 h and 168 h after the injury, and suggest
that at these time points p38 is an essential coordinator of network efforts that are more directed
towards differentiation of cells to promote healing.
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4.4.3 Potential Bystander Effects
The results of this study may be relatable to the bystander effect. The bystander effect is
typically referred to as the observation of similar deleterious effects or even death of unexposed
cells, when neighbor cells have been affected by some injurious event.86 The effects observed in
neighboring cells are believed to be due to signals that affected cells release as a result of
changes in their gene expression induced by the injury.86 The most well studied injurious event
is that of radiation exposure.87 The bystander effect is also observed following transfection, as
transfected cells have been shown to transfer death signals to their neighboring cells.88 The
bystander effect has also been associated with chemical exposures.89, 90
While radiation, transfection, and chemically induced bystander effects have been
extensively studied, the notion that similar bystander effect mechanisms may occur in physically
induced traumatic tissue injury has received little attention. Tissue functioning is greater than
the sum of its cellular parts.91 Individual cells are directed in large part by extracellular signaling
that mediates cell-to-cell communication as well as the interaction of cells with the extracellular
matrix. These interactions are modulated by the tissue microenvironment, where cytokines
predominate.91 Extracellular signaling is responsible for the integration of multi-cellular damage
responses, and the bystander effect may simply be the result of this extracellular signaling that
modulates cellular repair and death programs.15 The bystander effect may also occur in the case
of physical traumatic injury. The data obtained in this work are suggestive of this, as similar
protein responses were often obtained when comparing the fracture site to 1 cm away. These
particular protein responses were not the same as the responses in the uninjured leg. These
similar responses were most frequently observed for phosphorylated protein responses at the 0 h
time point. Immediate responses are coordinated by phosphorylation, and cytokines and MAPKs
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have been implicated as mediators of the bystander effect.87, 88, 90, 92 Akt and GSK-3α/ß were
among the phosphorylated proteins with similar responses at the fracture site and 1 cm away.
Previous research has associated the Akt-GSK-3α/ß pathway with bystander effect signals.93
The analysis identified total MEK1 as an important protein to the 168 h tissue response at
the fracture site, 1 cm away, and by the across locations analysis. In the uninjured analysis total
MEK1 was highlighted at the 24 h time point and phosphorylated MEK1 was highlighted at the
168 time point. MEK1 was also highlighted by the across time points analysis for the uninjured
leg. MEK1 is recognized as a necessary regulator of myogenesis in skeletal muscle. Whether or
not MEK1 signaling has a stimulatory or inhibitor effect on myogenesis depends on the specific
stage of healing process.94
Due to their involvement in the regulation of inflammatory mediators MAPKs, GSK-3α/ß
and p38 in specific, have received attention as therapeutic targets for the treatment of a variety of
conditions.73, 95, 96 These two proteins were heavily indicated as being important to the tissue
response by the analysis performed in this work due to their identification at multiple time points
and locations. This demonstrates the potential utility of the presented approach as an initial
screen to identify potential therapeutic targets.

4.5 Conclusions
This study has shown that following traumatic injury, key markers of wound healing
display spatial concentration gradients with regard to the injury site. These gradients represent
biomarkers that may be used to define the ZOI, and aid in the spatial assessment of the state of
injured tissue. The cytokines and MAPKs studied here represent biomarkers worth pursuing in
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the development of clinical assays aimed to guide the effective assessment and treatment of
wounds.
It can be seen that it is difficult to understand and represent integrated stress responses of
tissue signaling networks, even with an incomplete coverage of just a few proteins present in
muscle tissue. The analysis presented here sheds light on the network mechanisms involved in
the muscle response to injury, mapping dynamic condition specific relationships over both time
and space. The analysis revealed IL-6 as an important spatial marker of the ZOI, and revealed
GSK-3α/ß as an extremely important protein in the muscle injury response to blunt force trauma.
Some of the results obtained here align with previous research studies in identifying the same
proteins as important to muscle tissue response, while other proteins identified by the analysis
have not previously been recognized as being important to the response. The vast majority of
studies investigating the specific roles of proteins under injurious inflammatory inducing
conditions are performed in vitro, typically focusing on the up or down regulation of a few select
proteins.

Specifically, much of the current knowledge regarding how cytokines affect

intracellular signaling comes from studies of isolated immune cells. Different cells can respond
differently to the same cytokines. The results presented here are unique in that they reflect the
entire tissue (consisting of both immune cells and muscle cells) response to trauma, and reflect
the networked response of multiple proteins across varying degrees of perturbation. Current
technology does not yet permit us to monitor in real time all of the interactions occurring
between signaling molecules in living organisms and directly visualize the structure and
dynamics of the network they comprise. The network analysis approach presented in this work
can help fill this gap by providing an integrated data-driven description of how biological
networks respond to stress.
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4.6 Future Directions
The millions of molecules comprising entire organisms can be considered as one large
signaling network. The network analysis approach presented here only captures a small portion
of this expansive network. In the future, more biological information could be extracted by
monitoring more protein targets, and by incorporating additional network components such as
hormones, mRNA, and scaffolding proteins in the analysis. In this analysis, the only type of post
translational modification monitored was that of phosphorylation and only at one site on each
target protein. Many proteins can undergo a multiple types of post-translational modifications
and at multiple amino acid sites. The number and diversity of nodes included in the network
analysis can be expanded to include these modifications and provide richer biological
information pertaining to any problem of interest. The developed approach can easily be applied
to larger datasets, and is only limited by the technology used to simultaneously detect node
targets. Additionally, this work focused on a single graph theory parameter. There are many
different graph theory parameters, and even more are sure to be developed in the future.
Different graph theory parameters can be used to provide unique interpretations and perspective.
In future work, the utility additional centrality parameters will be explored.
Spatial molecular response comparisons were made in this work to identify objective
predictors of acute wound healing outcomes that could potentially be used in point of care assays
to assist surgeons in making appropriate surgical decisions. Following traumatic injury the
boundaries of viable tissue are of particular importance to surgeons who must decide the proper
regions of debridement. If too little tissue, is removed patients will need to be subjected to
repeated costly and painful surgical procedures. If too much tissue is removed, optimal healing
and recovery may be hindered. Currently, the assessment of viable tissue in the operating room
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is entirely based on visual inspection of the injured tissue. An approach to predict cell death by
monitoring the early phosphorylation of key proteins has been developed by Vrana et al.97 This
approach has currently only been applied to predict cell death in vitro following chemical
exposure. The application of this approach to phosphorylation responses obtained from injured
muscle tissue could provide the basis for developing point of care assays to improve surgical
decision making.
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